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Resumo 
 
 Os glioblastomas são os tumores cerebrais mais comuns, recorrentes e com uma 
alta taxa de mortalidade, principalmente devida à ineficácia das terapias usadas que 
incluem a combinação de cirurgia, radioterapia e quimioterapia. Os resultados 
insatisfatórios obtidos com o uso da quimioterapia atual, como a carmustina e a 
temozolomida, são fortemente atribuídos à resistência adquirida pelo tumor mediada 
principalmente pela glicoproteína-P e pela enzima metil-guanina metil-transferase 
(MGMT).  
A doxorubicina (DOX) mostrou ser eficaz contra alguns tumores periféricos e 
gliomas malignos em estudos in vitro. No entanto, não é possível o seu uso para o 
tratamento de glioblastomas visto que este fármaco não atravessa a barreira 
hematoencefálica (BHE) devido à sua baixa lipofilicidade e elevado peso molecular. 
Também o metotrexato (MTX) é usado desde há muito tempo como um potente fármaco 
anticancerígeno mas também apresenta dificuldade em atravessar a BHE, sendo 
necessário uma administração sistémica em doses elevadas e potencialmente tóxicas a 
nível periférico, para se atingir uma dose efetiva no cérebro. Uma vez que as vias de 
administração dos fármacos quimioterapêuticos são tecnicamente difíceis e dolorosos 
para os pacientes, são necessários métodos mais práticos e seguros. Desta forma, e tendo 
em conta a capacidade que a metanfetamina (MET) possui para aumentar 
transitoriamente a permeabilidade da BHE, o objetivo deste trabalho foi avaliar se a MET 
interferia com os efeitos da DOX ou MTX, analisando especificamente a viabilidade 
celular, migração, quimiotaxia e ciclo celular. 
 Os resultados deste trabalho demonstraram que a MET na concentração de 1 µM 
não interfere na viabilidade, migração ou ciclo celular das células de glioblastoma 
humano, a linha celular U-118. Da mesma forma, esta droga não alterou os efeitos na 
viabilidade celular, migração, quimiotaxia e no ciclo celular induzidos por DOX ou 
MTX. Contudo, a MET por si só conseguiu diminuir a quimiotaxia das células de 
glioblastoma, sendo este efeito semelhante ao que foi induzido pela DOX ou MTX 
quando administrados individualmente. No que diz respeito ao efeito da DOX, este 
fármaco levou a uma diminuição da viabilidade celular, migração e quimiotaxia assim 
como a uma paragem no ciclo celular na fase G2 e a uma diminuição na expressão da 
ciclina A. Também o MTX diminuiu a viabilidade, migração e quimiotaxia das células de 
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glioblastoma, do mesmo modo que afetou o seu ciclo celular levando a uma paragem das 
células na fase S. 
 Em suma, podemos concluir que a DOX e o MTX têm um efeito tóxico nas 
células de glioblastoma e que a METH, a uma concentração que aumenta a 
permeabilidade das células endoteliais, não interfere com o efeito da DOX ou MTX. 
Deste modo, consideramos que esta abordagem merece ser alvo de um estudo mais 
aprofundado de forma a melhor esclarecer o uso da MET como uma abordagem 
terapêutica em situações de tumores cerebrais. 
 
Palavras chave: Glioblastoma; Metanfetamina; Doxorubicina; Metotrexato; Barreira 
hematoencefálica.  
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Abstract 
 
 Glioblastomas are the most common primary tumors of the brain with a high 
recurrence and mortality rate justified by the ineffectiveness of current therapeutics that 
include combinations of surgery, radiotherapy and chemotherapy. The unsatisfactory 
results with current chemotherapeutic agents, such as carmustine and temozolomide, have 
been strongly attributed to tumor cell resistance mainly mediated by P-glycoprotein and 
the enzyme methylated DNA-protein cysteine methyltransferase (MGMT).  
Doxorubicin (DOX) showed to be effective against some peripheral tumors and 
malignant glioma tumors in vitro. However, it is not possible to use DOX for the 
treatment of glioblastomas since it cannot cross the blood-brain barrier (BBB) due to its 
low lipophilicity and high molecular weight. Also, methotrexate (MTX) has been used for 
long time as a potent anticancer agent but also shows limitations to cross the BBB. 
Consequently, to achieve an effective dose of MTX in the brain, high and potential toxic 
doses of MTX should be administered systemically. Since the conventional 
administration routes for chemotherapy drugs delivery are difficult and painful for the 
patients, more practical and safe delivery methods are needed. In this way, due to the 
ability of methamphetamine (METH) for transiently increase BBB permeability, the aim 
of the present work was to evaluate whether METH could interfere with DOX and MTX 
effects, focusing particularly on the cellular viability, migration, chemotaxis and cell 
cycle of glioblastoma cells.  
 Our results demonstrated that 1 µM METH did not interfere in U-118 
glioblastoma cell viability, migration and cell cycle. In the same way, METH did not alter 
the effects induced by DOX or MTX on cell viability, migration, chemotaxis and cell 
cycle. However, METH by itself impaired the glioblastoma cells chemotaxis, having 
similar effects to those observed with DOX or MTX alone. Regarding DOX effects in 
glioblastoma cells, this drug was able to decrease cell viability, migration and chemotaxis 
and led to a cell cycle arrest at G2 phase and to a decrease on cyclin A expression. 
Similarly, MTX induced a decrease in glioblastoma cell viability, migration and 
chemotaxis and a cell cycle arrest in the S phase. 
 Overall, we can conclude that both DOX and MTX have a toxic effect in 
glioblastoma cells and that METH, in a concentration that increases endothelial cells 
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permeability, does not interfere with DOX or MTX effect. Thus, we consider that this 
approach should be explored in order to clarify the use of METH as a therapeutic 
approach involving brain tumors.  
 
Key words: Glioblastoma; Methamphetamine; Doxorubicin; Methotrexate; Blood-Brain 
Barrier. 
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CHAPTER 1 
Introduction 
1.1. Brain tumors 
1.1.1. Epidemiology 
 
Brain tumors are relatively rare but with a high death rate among the diagnosed 
cases. Indeed, 74% of the detected cases lead to death. Worldwide, the incidence of 
primary brain tumors is about 7 per 100,000 individuals per year, being 2% of all primary 
tumors (Furnari et al., 2007). In Europe, the standardized incidence of primary Central 
Nervous System (CNS) cancers ranges from 4.5 to 11.2 cases per 100,000 men and from 
1.6 to 8.5 per 100,000 women (Ferlay et al, 2008). Brain tumors are the most common 
solid tumors of childhood and account for 20% of all malignancies in this age group 
(Cokgor et al., 1998). Moreover, there is worldwide geographic variation in the incidence 
of brain tumors. For example, malignant brain tumors occur in Japan with less than half 
the frequency of that in Northern Europe. Countries that report a high incidence of 
malignant brain tumors include Australia, Canada, Denmark, Finland, Sweden, New 
Zealand, and the United States of America. On the other hand, areas of the world with a 
lower incidence, such as Philippines and India, have an incidence four times less than the 
high-incidence countries. Nevertheless, there are some difficulties to obtain exact 
geographic comparisons, especially between countries, because all over the world there 
are different diagnostic practices and incomplete brain tumor reports. In addition, higher 
incidence rates appear in countries with better access to health care and better medical 
cares (Wrensch et al., 2002). 
1.1.2. Risk factors 
 
Concerning risk factors for brain tumors, exposure to therapeutic doses of ionizing 
radiation is the only established potentially modifiable brain risk factor. Evidence for an 
association with head injury, foods containing N-nitroso compounds, occupational risk 
factors, and exposure to electromagnetic fields are inconclusive (Fisher et al., 2007). 
Other factor that could increase the risk for brain cancer is the use of cell phone, and 
several recent studies provide some evidence for an association between long term cell 
phone use and glioma. Specifically, Khurana and collaborators (2009) showed that the 
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use of cell phone for ≥10 years approximately doubles the risk of being diagnosed with a 
brain tumor on the same side of the head as that preferred for cell phone use. 
Additionally, there is suggestive evidence of an association between immunologic factors 
and gliomas. Patients with atopic syndrome have a reduced risk of gliomas (Linos et al., 
2007) and patients with glioblastoma who have elevated IgE levels appear to live longer 
than those with normal levels (Wrensch et al., 2006). Gene polymorphisms that affect 
detoxification, DNA repair, and cell-cycle regulation have also been implicated in the 
development of gliomas (Fisher et al., 2007). Approximately 5% of patients with 
malignant gliomas have a family history of gliomas. Some of these familial cases are 
associated with rare genetic syndromes, such as neurofibromatosis types 1 and 2, the 
Li−Fraumeni syndrome (germ-line p53 mutations associated with an increased risk of 
several cancers), and Turcot’s syndrome (intestinal polyposis and brain tumors) (Fisher et 
al., 2007). Brain tumors include a group of different tumor entities anatomically close to 
each other but diverse in terms of morphology, site, molecular biology and clinical 
behavior and presumably etiology (Crocetti et al, 2012). They can be divided into two 
major groups: intrinsic tumors arising from cells within the CNS or its coverings, and 
those which arise from a primary tumor outside the CNS, and invade the brain as a 
metastatic disease. The group of intrinsic tumors can be further divided into 
neuroepithelial tumors (arising from glial and neuronal cells or their precursors within the 
brain and spinal cord), and non-neuroepithelial tumors (arising from cells within blood 
vessels, arachnoidal cells, cranial and spinal nerve sheath cells, and blood vessels). 
Metastatic brain tumors, which are the most common intracranial tumors and occur in 15-
40% of cancer patients, most commonly arise from malignant melanoma, lung, breast and 
kidney tumors (Ironside et al., 2012). Nevertheless, the frequency of metastases has 
increased because it is now possible to detect small tumors due to the improvement 
achieved in magnetic resonance imaging techniques (Tosoni et al., 2004). Also, the 
incidence of CNS metastases has increased in recent years, probably due to the longer 
survival of patients given aggressive treatments for primary tumors. Lung cancer is the 
main primary source of metastases to the CNS, causing brain metastases in 9.7-64% of 
the patients. On the other hand, in patients with breast cancer the incidence of brain 
metastases is lower (2-25%) and it appears to exist a direct relation between stage of 
disease and incidence of the metastases. Interestingly, the occurrence of brain metastases 
in aged patients (more than 70 years old) with breast and lung cancer is rare, and this may 
be related with a less aggressive disease in the elderly patients (Schouten et al., 2002). 
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With an incidence between 4% and 20%, melanoma is other of the most common form of 
cancer that spread to the CNS. Metastases in CNS from colorectal cancer involving the, 
genitourinary tract and sarcoma are less frequent (1%) and the primary tumor is unknown 
in 15% of patients with this kind of metastases. Most brain metastases are due to 
hematogenous spread from the primary tumor, usually via arterial circulation. Inside the 
brain, metastases tend to localize in the area of the gray-white junction and in border 
zones of the major cerebral vessels. This particular distribution is due to the progressive 
decrease in the size of blood vessels in these areas acting as a trap for emboli. 
Neuroimaging studies have shown that brain metastases are multiple in two thirds of 
patients affected. It seems that histology influences the number of brain metastases since 
most colon, breast and renal cell tumors produce single lesions, whereas melanoma and 
lung cancer have a greater tendency to form multiple metastases (Tosoni et al., 2004). 
1.1.3. Pathology 
 
Brain tumors are classified on a scale of I to IV defined by the World Health 
Organization (WHO), and it is based on tumor genetics and histopathological 
characteristics pointing the degree of malignancy and subsequent propensity for 
aggressive behavior (Louis et al, 2007). Thus, these tumors are classified on the basis of 
histopathology into the following major groups: gliomas, including grade I astrocytoma 
(are generally benign and frequently curable with complete surgical removal), grade II 
astrocytoma, anaplastic astrocytoma (grade III), glioblastoma (grade IV), 
oligodendroglioma, and ependymoma, that arise from neuroepithelial tissue; tumors of 
meninges (including meningioma and hemangioblastoma); and germ cell tumors and 
tumors of the sellar region (including pituitary tumors and craniopharyngioma), that arise 
from non-neuroepithelial tissue (Fisher et al, 2007). 
Generally, the incidence rates of meningioma and glioblastoma among adults 
increase with advancing age. In children and adolescents, incidence rates of all non-germ 
cell histologies decrease through childhood and adolescence, whereas the incidence of 
germ cell tumors reaches a peak during the adolescent years (Crocetti et al., 2012).  
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1.2. Glioblastomas 
1.2.1 Classification 
 
 From all types of malignant brain tumors, the most common and lethal is 
glioblastoma  multiforme also called glioblastoma, a grade IV astrocytoma (Louis et al, 
2007). The incidence of these tumors has increased over the past two decades, especially 
in older people (Fisher et al, 2007). In spite of surgery and adjuvant therapy 
advancements, the prognosis remains unfavorable, with a median survival of 12-18 
months (Hou et al, 2006). Specifically, the median survival is about 10-15 months for 
glioblastoma and up to 30-50 months for anaplastic astrocytoma, despite maximal 
surgical resection, postoperative radiotherapy and chemotherapy (Nieder et al., 2009). 
This type of tumors can emerge in any region of the CNS, but is more frequent in 
subcortical white matter of cerebral hemispheres. The hallmark histopathological features 
of this tumor include nuclear atypia, necrosis, hypercellularity, and microvascular 
proliferation (Ironside et al, 2012). Malignant gliomas typically contain both neoplastic 
and stromal tissues, which contribute to their histologic heterogeneity and variable 
outcome. Molecular studies, such as gene-expression profiling, allow a better 
classification of these tumors and separation of the tumors into different prognostic 
groups (Collins et al., 2007). 
1.2.2. Molecular pathology 
 
Glioblastomas can develop de novo or through progression from low-grade or 
anaplastic astrocytomas, which are called primary or secondary glioblastomas, 
respectively. These subtypes of glioblastoma represent distinct disease entities that evolve 
through different genetic pathways, affect patients at different ages, and are likely to 
differ in prognosis and response to therapy. Primary glioblastomas are more frequent in 
older patients and typically show epidermal growth factor receptor gene (EGFR) 
overexpression, PTEN (phosphatase and tensin homolog) mutations, CDKN2A (cyclin-
dependent kinase inhibitor 2A gene) (p16) deletions, and less frequently, MDM2 (murine 
doble minute 2 gene) amplification. Secondary glioblastomas develop in younger patients 
and often contain TP53 mutations as the earliest genetic detectable alteration. There are 
more subtypes of glioblastomas with intermediate clinical and genetic profiles, and a 
good example is the giant-cell glioblastoma that clinically and genetically occupies a 
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hybrid position between primary and secondary glioblastomas (reviewed by Kleihues et 
al., 1998). These mutations in the glioblastoma genetic profile also contribute for their 
chemotherapeutic resistance since some of these mutations are in genes that protect cells 
against cell death. For instance, the PI3K/AKT/mTOR pathway that regulates several 
normal cellular functions critical for tumorigenesis, including cellular proliferation, 
growth, survival and mobility, is usually deregulated in malignant gliomas, probably due 
to receptor tyrosine kinases activation and/or PTEN loss, which regulates negatively the 
PI3K/AKT/mTOR pathway (Hu et al., 2005) (Figure 1).  
Genetic mutations in glioblastomas induce the overexpression of specific growth 
factors that induce the formation of new blood vessels, a process called angiogenesis. The 
expression level of vascular endothelial growth factor (VEGF) is directly correlated with 
tumor grade and malignancy, and can be 10 fold more expressed in high grade gliomas 
compared with low grade (Arko et al., 2010). Due to the formation of new vessels, 
glioma cells are able to increase their oxygen and nutrient supply which increase the 
chance of tumor cell survival. In fact, malignant gliomas are highly-vascularized solid 
tumors and have a great invasive nature. Several studies have suggested that gliomas are 
capable of moving throughout the brain because of chemical modulation of the 
surrounding extracellular matrix (ECM). This migration is thought to occur via secretion 
of matrix metalloproteinases, such as MMP-9, that causes degradation of the ECM 
(Chetty et al., 2012).  
 Recent studies indicated that glioma samples are characterized by increased 
expression of some chemokines receptors (Oh et al., 2001, Maru et al., 2008, Zhou et al., 
2002). Chemokines are the most important and best known group of chemotactic proteins 
and exert a direct role in regulation of leukocyte trafficking  during immunosurveillance 
and inflammation. Nevertheless, chemokines participate in many other physiological 
processes, such as immune system cell differentiation and homeostasis, and in both 
angiogenesis and development (Gerard et al., 2001). Regarding tumors, chemokines are 
known to address intratumoral trafficking of immune cells, and to modulate tumor 
proliferation, metastasis and angiogenesis (Vandercappellen et al., 2008). The most 
known chemokines receptors with an increased expression in human glioma are CXCR3 
(G protein-coupled receptor 9 or CD183) (Maru et al., 2008) and CXCR4 (Sciaccaluga et 
al., 2010), which belong to the CXC chemokine receptor subfamily. CXCR3 has three 
endogenous ligands, monokine induced by gamma interferon (MIG or CXCL9), 
interferon gamma-induced protein 10 (IP-10 or CXCL10) and interferon-inducible T-cell 
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alpha chemoattractant (ITAC or CXCL11), while CXCR4 has the chemokine stromal-
derived factor-1 (SDF-1 or CXCL12) as a ligand (Bonavia et al., 2003). Studies with 
astrocytoma and glioblastoma cells suggested that the increased expression of chemokine 
receptor/ligand pair, CXCR3/CXCL10, has an important role in the proliferation, growth 
and increase DNA synthesis of these cells types (Maru et al., 2008; Liu et al., 2010). 
Meanwhile, the CXCR4 expression on brain tumor cells at high levels has negative 
prognostic significance (Bian et al., 2007). The studies of Carmo and others (2010) 
demonstrated that the activation of CXCR4 by CXCL12 promoted proliferation, survival, 
migration and chemotaxis of glioma cells, confirming that CXCL12/CXCR4 signaling 
pathway may contribute to the growth and invasive characteristics of glioblastomas. 
Moreover, it is due to this malignant invasive nature that surgical resection of gliomas is 
not so efficient. Even though surgical resection has been shown to improve patient 
survival, some glioblastomas spread and evade critical areas of the brain that are unable 
to be surgically removed, because of the risk of compromising the neuronal function of 
patients. These residual tumor cells are then able to invade other brain tissues, causing the 
high incidence of glioblastoma recurrence (reviewed by Furnari et al., 2007). 
 
 
Figure 1 - Key deregulated pathway in human gliomas. Many different genetic and molecular 
alterations in human gliomas lead to modifications of the same signaling pathways that result in 
brain tumor growth and progression. Red indicates oncogenes that are overexpressed or amplified 
in glioblastoma samples, and blue indicates tumor suppressor genes that are somatically mutated 
or deleted (except for P27 and P21) (Adapted from Chen et al., 2012). 
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1.2.3. Recurrence 
 
Glioblastoma recurrence is inevitable, despite extensive surgical intervention. 
Indeed, after a median patient survival time of 32 to 36 weeks, it has been reported that 
90% of patients with glioma would experience tumor recurrence at the original tumor site 
or near the original tumor (2 to 3 cm from the border of the original lesion). It is usual to 
define glioblastoma recurrence as a change from an interval of time with tumor absence 
followed by a complete loss of tumor control. The treatment approaches for recurrent 
glioblastomas are hindered by the lack of uniform definition and criteria of recurrence, 
institutional variability in treatment, and the heterogeneous nature of recurrence in glioma 
spatial location and acquired resistance to chemotherapy (Hou et al., 2006). 
Glioblastomas assume a challenge in neuro-oncology field not only because of 
their, infiltrative nature, propensity for recurrence and resistance to conventional therapies 
(Furnari et al, 2007) but also because of blood-brain barrier (BBB) that limits the 
entrance of systemically administered chemotherapeutic drugs into the brain (Parney et 
al., 2003). 
1.3. Therapeutic approaches for glioblastomas   
1.3.1. Surgery 
The classic treatment of glioblastomas includes, on the most part of the cases, 
surgery followed by radiotherapy and then chemotherapy. Surgical removal of the tumor, 
not only improves the patient survival time but is crucial for the acquisition of tumor 
tissue samples that are used to confirm the histological type and malignancy of the tumor. 
Surgery can also reduce intracranial pressure and mass effect, improving patients’ 
neurological status and the efficacy of adjuvant therapy (Hou et al., 2006). However, 
surgery seems to be more effective in first-line treatment. When recurrence occurs re-
operation is a possible option, but there is an increased risk of surgery-related morbidity 
and mortality (reviewed by Niyazi et al., 2011).  
1.3.2. Radiotherapy 
Radiotherapy substantially improves survival and is generally administered with a 
total dose corresponding to the upper limit of a safe dose. However, cognitive dysfunction 
and radionecrosis may occur with this regimen, especially when concomitant 
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chemotherapy is given. Other techniques, such as brachytherapy, adjunction of 
radiosensitisers, or hyperfractionation have demonstrated no benefits in comparison with 
standard radiotherapy (reviewed by Behin et al., 2003). As happen with the surgery, 
oncologists have been highly reluctant to re-treat local recurrences in the brain, although 
radiation is proven to be effective in primary glioblastomas. This reluctance is based on 
the assumption that CNS tissues are not capable of repair radiation injuries (reviewed by 
Niyazi et al., 2011). So, due to the possibility of severe side effects there is a limited use 
of radiation in re-treatment settings of recurrent malignant gliomas (reviewed by Niyazi et 
al., 2011). 
1.3.3. Chemotherapy 
Regarding the treatment options for glioblastomas, chemotherapy is the most 
versatile strategy because possesses greater range of choices. Chemotherapeutic drugs are 
usually administered following surgical resection of tumor and irradiation of glioblastoma 
lesions. Drugs could be given systemically and others could be given in situ, directly in 
the tumor.  
Over the past 30 years, no significant changes in the standard treatment of 
malignant gliomas have been observed. In 1980, the possible treatments were: semustine 
(MeCCNU), radiotherapy, carmustine (BCNU) plus radiotherapy, or semustine plus 
radiotherapy. Patients who received radiotherapy alone or in combination with a 
nitrosourea (carmustine or semustine) had a significant improvement in overall survival 
when compared to patients treated with other combinations. In 1996, the FDA (Food and 
Drug Administration) approved a polyanhydride biodegradable polymer wafer containing 
BCNU (1-3-bis(2-chloroethyl)-1-nitrosourea), known as Gliadel®, for the treatment of 
recurrent gliomas. Patients with recurrent tumors and those that made primary resections 
for newly diagnosed tumors who had wafers placed at the time of their second surgeries, 
were found to have approximately 2 months of survival benefit (Brem et al., 1995; 
Westphal et al., 2003). However, the most significant advance in malignant glioma 
therapy for newly diagnosed tumors, since radiation therapy, has been the administration 
of temozolomide (TMZ). Temozolomide is an oral alkylating agent approved by the FDA 
in 1999 after the European Organization for Research and Treatment of Cancer (EORTC) 
and National Cancer Institute of Canada (NCIC) phase III trial demonstrated an improved 
median survival. So, TMZ received FDA approval for refractory anaplastic astrocytoma, 
followed by a first-line indication for glioblastoma (Stupp et al., 2005, 2009).   
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More recently, other experimental therapies have been raised. Irinotecan, a 
topoisomerase 1 inhibitor, provide a viable treatment option for tumors resistant to 
temozolomide. It is also an alternative choice for recurrent malignant gliomas despite the 
controversy regarding its ability to pass through the blood-brain barrier (BBB). However, 
as a single agent, irinotecan showed disappointing results in the treatment of recurrent 
malignant gliomas. In 2009, FDA has granted accelerated approval for single 
bevacizumab, the humanized monoclonal antibody against VEGF, for the use in patients 
with glioblastoma that has progressed despite previous therapy. Furthermore, 
bevacizumab has generally been used in combination with cytotoxic agents. However, the 
efficacy of bevacizumab and irinotecan combination to treat glioblastoma remains to be 
clarified (Xu et al., 2010). 
There is a range of chemotherapeutic drugs that have been investigated against the 
different types of malignant gliomas, in vivo and in vitro, but the drugs that are most 
clinically relevant to current malignant gliomas are summarized in Table 1.  
 
Table 1- Summary of current treatments for malignant gliomas (adapted from Wen and 
Kesari, 2008).  
 
Type of tumor 
 
 
Therapy 
 
Newly diagnosed tumors 
 
 
 
Glioblastomas 
(WHO grade IV) 
 
 
Maximal surgical resection plus radiotherapy, or plus 
concomitant and adjuvant Temozoline (TMZ) or 
carmustine wafers (Gliadel). 
 
Anaplastic astrocytomas 
(WHO grade III) 
Maximal surgical resection, with the following options 
after surgery (no accepted standard treatment): radiotherapy 
plus concomitant and adjuvant TMZ or adjuvant TMZ 
alone. 
 
Recurrent tumors Reoperation in selected patients, carmustine wafers 
(Gliadel), conventional chemotherapy, e.g. lomustine, 
carmustine, PCV lomustine, procarbazine, vincristine, 
carboplatin, irinotecan, 
etoposide, bevacizumab plus irinotecan, or experimental 
therapies. 
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       Despite the well known advantages of chemotherapeutic drugs, there are also 
some limitations. The oldest drug used for glioblastoma and recurrent malignant tumors, 
carmustine (BCNU), has several side effects especially because of its cytotoxicity. The 
main effect of BCNU is mediated by the cross-link of DNA strands by its 
chloroethylation of a nucleophilic site on one DNA strand and displacement of a chloride 
ion on the other strand. Chloroethylation produces ethyl bridges between these two DNA 
strands. This cross-linking causes the disruption of DNA that in the end hinders RNA 
synthesis (Bota et al., 2007). Traditional methods of delivering BCNU to the tumor site, 
such as intravenous perfusion or oral administration, cause debilitating side-effects 
including hematological depression, cytotoxic effects on kidney, liver, lungs and CNS, 
brain edema and seizures (Wang et al., 1999; Guerin et al., 2004). Also, because of the 
short half-life of BCNU, there is an insufficient drug exposure and distribution 
throughout the brain (Bota et al., 2007). The development of localized delivery of BCNU 
directly to the glioblastoma tumor is also unattractive to patients. In order to increase the 
exposure of the tumor to the drug (Brem et al., 2001), Gliadel® wafer is administered as 
an intracranial implant and requires surgical intervention for placement, and the wafers 
are very thin and fragile. Broken wafers contribute to increased intracranial edema and a 
potential toxic release of chemotherapeutic drug leading to fatal clinical complications 
(Arifin et al., 2009).  
 A major limitation of chemotherapy with BCNU involves a resistance mechanism 
(Bredel, 2001) mediated by a DNA-repair enzyme, MGMT (methylated-DNA-protein-
cysteine methyltransferase). This DNA-repair protein is inherent to a majority of human 
brain tumors, and protects tumor cells from the cytotoxic effects of alkylating agents 
(Silber et al., 1993). MGMT also contributes to resistance to TMZ. Following oral 
absorption, TMZ is hydrolyzed in aqueous solution to methyl-triazeno-imidazole-
carboxamide (MTIC). MTIC is rapidly converted to the inactive 5-aminoimidazole-4-
carboxamide (AIC) and to the electrophilic alkylating methyldiazonium action that 
transfers a methyl group to DNA. The DNA-methyl adducts are responsible for the 
cytotoxicity. Alkylation of the O6 position of guanine accounts for only about 5% of 
DNA adducts, but is primarily responsible for the cytotoxic effects of TMZ. The N7 of 
guanine and the N3 of adenine represent the majority of DNA-methyl adducts. The O
6
-
methylguanine (O
6
-meG) lesion leads to DNA double strand breaks and subsequent cell 
death via apoptosis and/or autophagy. MGMT repairs the O
6
-meG lesion, and thus high 
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levels of MGMT are thought to contribute to resistance to TMZ. Chemotherapeutic 
resistance is not the only limitation of using TMZ. TMZ has dose-limiting toxic side-
effects that could be seen as leucopenia, seizures and myelosuppression, nausea, 
constipation and headache (reviewed by Villano et al., 2009). 
 In general, resistance to chemotherapy in brain tumors is complex and may 
involve multiple mechanisms besides the one related with MGMT and alkylating agents. 
These may include: ATP-dependent efflux of cytotoxic agents by transmembrane 
transport proteins encoded by the multiple drug resistance 1 (Mdr1) gene and the 
multidrug resistance-associated protein-1 (MRP1) gene; DNA damage caused by 
quantitative alteration topoisomerase IIα (Topo IIα) expression; deficiency in DNA 
mismatch repair pathways and increased nucleotide excision repair as a result of an 
altered activity of poly(ADP)-ribose polymerase; enhanced detoxification of alkylating 
agents by the glutathione (GSH)-linked enzyme system; an impaired ability to commit 
apoptosis; and changes in the expression status of resistance-markers due to elevated 
levels of activity of protein kinase C (PKC) (Bredel, 2001).  
 Some drugs are used in combination with radiotherapy or with the traditional 
chemotherapy in order to minimize drug resistance and maximize tumor cell kill. One of 
those drugs is Doxorubicin. 
1.4. Doxorubicin 
 Doxorubicin (DOX) or Adriamycin, is an anthracycline antibiotic with strong 
antitumor action against several tumors, such as lymphoblastic leukemias, sarcomas, 
lymphomas, carcinomas of the head and neck, and cancers of the breast, pancreas, 
stomach, liver, ovary, lung and prostate. DOX is produced by the Streptomyces peucetius 
varieta caesius and blocks DNA and RNA synthesis by inhibiting topoisomerase II 
(Lesniak et al., 2005). The primary mechanism of action of DOX appears to be the 
poisoning of the enzyme topoisomerase II which results in double-strand DNA breaks, 
leading to apoptosis. More recently, it was also demonstrated that DOX forms covalent 
adducts with DNA and these lesions are more cytotoxic than those induced by 
topoisomerase II impairment. Adducts are formed predominantly at 50-GC-30 sites in 
DNA where the DOX sugar group (daunosamine) is covalently linked to the N-2 amino 
group of guanine via an aminal (N–C–N) bond. The central carbon atom in the aminal 
bond is derived from formaldehyde, hence formaldehyde is an absolute requirement for 
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adduct formation. The resulting drug–DNA monoadduct is further stabilized through 
intercalation and hydrogen bonding with the second strand of DNA. Apoptosis resulting 
from doxorubicin–DNA adduct formation does not depend on topoisomerase II status, 
reflecting an independent mechanism of cell kill and highlighting that formaldehyde 
availability switches the mechanism of DOX action from topoisomerase II impairment to 
the formation of more cytotoxic DNA adducts (Swiff et al., 2006; Ugarenko et al., 2010) 
(Figure 2). 
 
 
 
Figure 2 - Mechanisms of action of doxorubicin: (A) Doxorubicin blocks DNA and RNA 
synthesis by inhibiting topoisomerase II (Adapted from Hurley, 2002), as well as by (B) forming 
adducts with DNA (Zhang et al., 2010). 
 
 
In vitro studies demonstrated that DOX is efficiently toxic to highly invasive 
human glioma cell lines, inducing cell death by apoptosis. DOX also showed to inhibit 
tumor invasion on a chorioallantoic membrane assay involving embryonated chicken eggs 
and highly invasive human glioma cell lines (Stan et al., 1999). Despite doxorubicin’s 
clinical effectiveness in the treatment of many malignant tumors, clinical trials involving 
systemic administration of the drug have demonstrated very limited efficacy in the 
treatment of gliomas (Hau et al., 2004). Very high doses of DOX must be administered 
systemically to exert its therapeutic benefit, which limits its usefulness because of the 
cardiotoxic and myelosuppressive side-effects induced by such a high doses of DOX.. 
The low lipophilicity and high molecular weight of DOX essentially prevent the delivery 
of the agent across the BBB (Lesniak et al., 2005). Thus, the limited efficacy of DOX 
when administered systemically can be explained by its poor penetration through the 
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BBB, as well as by its extrusion by P-glycoprotein (P-gp) (Neuwelt et al., 1981; Ohnishi 
et al., 1995; Lesniak et al., 2005).  
Different methods have been used to facilitate the transport of drugs into the brain. 
These methods include neurosurgical based invasive brain drug delivery which have, 
however, several limitations. So, most of the methods involve the use of osmotic 
biologically active agents (Bellavance et al., 2008). Additionally, some other drug 
delivery systems have been studied for BBB delivery, such as liposomes, microcapsules 
and osmotic pumps (Maysinger and Morinville, 1997). In vivo studies using animal 
models of malignant glioma suggest that DOX binds to nanoparticles and cross the intact 
BBB reaching therapeutic concentrations in the brain (Steiniger et al., 2004). To obtain 
better targeting efficiency, targeted liposomes and immunoliposomes have been proposed 
(Gong et al., 2011). However, even these methods show disadvantages, such as high 
systemic doses for BBB permeabilization, osmotic pumps failure that leads to potential 
toxic dumping, refilling of pumps that can originate infections, and parenchymal delivery 
which may cause a reaction at the delivery site (Maysinger and Morinville, 1997).   
 
1.5. Methotrexate 
 
 Methotrexate (MTX) is widely used as a chemotherapeutic agent for the treatment 
of many cancers, demonstrating consistent activity against a number of malignant tumors 
such as cervical and ovarian carcinoma, gastric and pancreatic carcinoma and leukemia 
(Hazard Substances Data Bank, 2005). MTX has also been found to have a successful 
therapeutic role in non-neoplastic diseases (e.g. psoriatic arthritis) as an anti-
inflammatory and immunosuppressive agent (Dalmarco et al., 2007). MTX is taken up by 
the cells via carriers, such as reduced folate carrier and folate receptor (Dixon et al., 
1994) and, once inside the cell, MTX acts as a potent competitive inhibitor of 
dihydrofolate reductase (DHFR). Inhibition of DHFR results in a depletion of the 
intracellular reduced folate pools required for the biosynthesis of purines and thymidines 
(Figure 3). Additionally, MTX is an antimetabolite that can penetrate the BBB when 
given in high doses by the intravenous route. Numerous studies of MTX or MTX-based 
chemotherapy in combination with whole-brain radiation therapy have been conducted in 
patients with primary CNS lymphoma, and these studies demonstrated that this 
combination results in the extension of progression-free survival when compared with 
historical series treated with whole-brain radiation therapy alone (Boiardi et al., 1999). 
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More recently, intravenous and intrathecal administration of MTX have largely replaced 
cranial irradiation for treatment of children with acute lymphoblastic leukemia 
(Brugnoletti et al., 2009). 
 
Figure 3 - MTX mechanism of action. MTX acts as a folic acid antagonist that binds to the 
active catalytic site of dihydrofolate reductase (DHFR). Folic acid is required in the synthesis for 
pyrimidine and purine nucleotides and for DNA synthesis. By inhibiting the enzyme DHFR, 
MTX prevents nucleic acid synthesis which leads to cell death (based on McGuire, 2003). 
 
Despite the above mentioned positive role of MTX treatment, this is often 
accompanied by strong side effects, such as nausea, vomiting, diarrhea, stomatitis, 
gastrointestinal ulceration, and mucositis (Frei et al., 1975). In cases of inadvertent 
intrathecal overdosage of MTX, severe neurotoxicity occurred, manifested as prompt 
burning or numbness in the lower extremities, stupor, seizures, and/or respiratory 
insufficiency. Moreover, brain damage or fatal necrotizing leukoencephalopathy may 
occur, but a complete recovery has been reported following aggressive therapy (Hazard 
Substances Data Bank, 2005). 
 MTX has a good potential as a chemotherapeutic drug against malignant gliomas 
since it shows acceptable results in CNS tumors, such as primary CNS lymphoma. 
However, there are still several risks related with the routes of administration and the 
dose limiting effects.  
CHAPTER 1 - Introduction 
31 
 Since DOX and MTX have limited penetration into the brain, the administration 
route is a serious concern for its effectiveness as chemotherapy for brain tumors. 
Additionally, both drugs are substrates of the P-gp (Varma et al., 2004) that is a great 
obstacle to CNS chemotherapy. Overall, BBB limits the entrance of chemotherapeutic 
drugs into the brain and the presence of P-gp both in endothelial cells and tumor cells will 
ultimately prevent the accumulation of drugs in the tumor. Both conditions are, indeed, a 
major impediment to the entry of many therapeutic drugs into the brain.  
1.6. Blood-brain barrier 
 
The blood-brain barrier (BBB), which is one of the blood-neural barriers, is 
present in almost all brain regions, except in the brain ventricular system (Cardoso et al., 
2010). BBB is a selective barrier formed by the endothelial cells surrounded by basal 
lamina, and by  astrocytes and pericytes. Both astrocytic endfeet and pericyte processes 
wrap the abuminal capillary surface and provide physical support and stability to the BBB 
(Figure 4). In recent years, the concept of a BBB has been significantly extended to the 
concept of a neuro(glial)vascular unit, which best describes the dynamic communication 
between brain endothelium, neurons, astrocytes, pericytes and microglia at the interface 
between the blood and brain parenchyma compartments (Hawkins and Davis, 2005). A 
healthy brain relies on all of the cells of the neurovascular unit to function properly and 
communicate with each other in order to maintain normal cognitive functions. 
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Figure 4 - Neuro(glial)vascular Unit. The cerebral endothelial cells have intercellular junctions 
that confer the barrier property of the BBB. Pericytes are distributed discontinously along the 
length of the cerebral capillaries. Both the cerebral endothelial cells and the pericytes are enclosed 
by, and contribute to, the local basement membrane which forms a distinct perivascular 
extracellular matrix (basal lamina 1, BL1), different in composition from the extracellular matrix 
of the glial endfeet bounding the brain parenchyma (BL2). Foot processes from astrocytes form a 
complex network surrounding the capillaries. Axonal projections from neurons contain vasoactive 
neurotransmitters that regulate local cerebral blood. Microglial cells have an immunovigilant 
function in the barrier (Adapted from Abbott et al., 2006).  
 
 
 BBB acts as a physical barrier since the complex tight and adherens junctions 
between adjacent endothelial cells force most molecular traffic to take a transcellular 
route across the brain endothelium, rather than moving paracellularly through the 
junctions. Small gaseous molecules, such as O2 and CO2 can diffuse freely through the 
lipid membranes, and this is also a route of entry for small lipophilic agents, including 
drugs like ethanol. The presence of specific transport systems on the luminal and 
albuminal membranes regulates the transcellular traffic of small hydrophilic molecules, 
which provides the transport by specific receptor-mediated transcytosis, or by the less 
specific adsorptive-mediated transcytosis (reviewed by Abbott et al., 2006). Moreover, 
extremely strait tight junctions are a key characteristic of the BBB and significantly 
reduce permeation of polar solutes through paracellular pathway between the endothelial 
cells from the blood plasma to the brain extracellular fluid (Figure 5).  
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Figure 5 - Transport mechanisms at the blood-brain barrier. The transporters of proteins and 
transcellular pathway are essential to suppress the nutritional needs. The paracellular transport is 
importat for ionic homeostasis. Transcytosis may occur at a low level but under physiological 
conditions (adapted from Abbott et al., 2006).   
 
The junctional complexes between endothelial cells include tight junctions (TJs) 
and adherens junctions (AJs). TJs consist of a complex of proteins spanning the 
intercellular cleft (occludin and claudins), and junctional adhesion molecules (JAMs). 
Claudins are the first “seal” of TJs and occludin confer the high electrical resistance to 
endothelial cells. These are transmembrane proteins that are linked to a number of 
cytoplasmic scaffolding and regulatory proteins, such as ZO-1, ZO-2, ZO-3 and cingulin 
(Reviewed by Abbott et al., 2010). In AJs, cadherin proteins span the intercellular cleft 
and are linked into the cell cytoplasm by the scaffolding proteins α, β and γ catenin. The 
AJs hold the cells together giving the tissue a structural support. Both TJs and AJs are 
essential for barrier properties and alterations of these proteins may lead to BBB 
dysfunction (Figure 6). 
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Figure 6 - Structure of brain endothelial junctions. The tigh junctional complex comprises 
junctional adhesion molecules (JAMs), occludin and claudins. The claudins and occludin are 
linked to the scaffolding proteins ZO-1, ZO-2 and ZO-3, which in turn are linked via cingulin 
dimers to the actin/myosin cytoskeleton within the cell. In the adherens junctions (AJs), VE-
cadherin proteins are linked to the actin cytoskeleton by the scaffolding proteins α-, β- and γ-
catenin (Adapted from Abbott et al., 2010). 
  
The BBB has several roles, including the brain supply with essential nutrients and 
to mediate efflux of many waste products. It restricts ionic and fluid movements between 
the blood and the brain, allowing specific ion transporters and channels to regulate ionic 
trafficproducing a brain interstitial fluid that provides an optimal medium for neural 
function (Abbott, 2004). More importantly, the BBB protects the brain from fluctuations 
in ionic composition that can occur after a meal or exercise, which would disturb synaptic 
and axonal signaling (Abbott et al., 2006). The barrier helps to keep separate the pools of 
neurotransmitters and neuroactive agents that act centrally (in the CNS) and peripherally 
(in the peripheral tissues and blood), so that similar agents can be used in the two systems 
without crosstalk. Because of its large surface area and the short diffusion distance 
between neurons and capillaries, the endothelium has the predominant role in regulating 
the brain microenvironment. 
There are several events that affect the BBB integrity altering the tight junctions, 
and in some cases the increased BBB permeability is a consequence of the pathology, as 
occurs in ischemic stroke and traumatic brain injury, whereas in other cases BBB opening 
may be a precipitating event, such as multiple sclerosis that is characterized by chronic 
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neuroinflammation. Also, some types of brain tumors characterized by edema such as 
glioblastoma appear to disturb the BBB function (Hawkins and Davis, 2005).  
 
1.7. Blood-brain barrier and glioblastomas 
 
 In malignant gliomas, such as glioblastoma, the BBB appears to be leaky, and this 
was visualized in some studies involving immunohistochemistry of plasma proteins using 
biopsy samples (Seitz et al., 1987), as well as by heterogeneous contrast enhancement in 
neuroradiological examination (Roberts et al., 2000). Some glioblastoma vessels, in 
particular those with endothelial hyperplasia, show abnormal morphological features of 
endothelial cells, like fenestrations, prominent pinocytotic vesicles, lack of perivascular 
glial endfeet, and loss and/or abnormal morphology of tight junctions (Engelhard et al., 
1999; Liebner et al., 2000). Accordingly, barrier-related molecular alterations were 
observed in immunohistochemical studies that revealed some transmembrane tight 
junction components down-regulated in glioblastoma microvessels, including occludin 
and claudin-3 (Papadopoulos et al., 2001; Wolburg et al., 2003). Also, claudin-5 and the 
intracellular tight junction component ZO-1 were additionally down-regulated in 
hyperplasic vessels (Liebner et al., 2000; Sawada et al., 2000). Abnormal expression of 
these tight junction components has been associated with the loss of the BBB integrity, as 
described for claudin-5-deficient mice (Nitta et al., 2003). However, this alterations use to 
occur at the tumor centre in contrast to what happens near the infiltrating edges of the 
tumor, where the BBB is still functional (de Vries et al., 2006). On the other hand, the 
BBB is usually preserved in low-grade (WHO grade II) gliomas (reviewed by Wolburg et 
al., 2012), making the delivery of chemotherapeutic drugs to these areas challenging. 
There are some hypotheses that may explain the pathogenesis of BBB dysfunction 
in malignant gliomas. One of the hypothesis is that dedifferentiated glioma cells have lost 
the ability of inducing BBB features in endothelial cells, making the excessive de novo 
vascular proliferations typical of glioblastomas functionally aberrant. Another hypothesis 
involves the fact that glioma cells might secrete factors that actively open or degrade 
initially intact BBB tight junctions. The finding of structural and functional BBB 
impairment even in the invasion area and in peritumoral brain (Dinda et al., 1993; 
Bertossi et al., 1997) suggests the involvement of factors that negatively interfere with 
normal BBB functions. 
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Highly invasive tumors own a great capacity of invasion and migration into the 
normal neural tissue with subsequent dispersion of isolated tumor cells far from the tumor 
core. Related with this, the expression or/and activity of different members of the MMP 
family can be increased in several glioblastoma cell lines and also in primary cultures of 
human samples (Hagemann et al., 2010). MMPs are proteolytic enzymes capable of 
degrading the extracellular matrix and consequently break down the connection between 
cells, including endothelial cells. MMP-9 acts as an important oncogene that improves 
invasiveness of cancer cells and high level of MMP-9 confers a poor prognosis in several 
cancers (Yang et al. 2011). A recent study hypothesized that MMP-9 increased activity 
may explain reduction on tight junctions proteins levels, like claudin-5, occludin and ZO-
1 proteins, that are essential to maintain BBB structure and function (Martins et al., 
2011). This fact could be one explanation for the loss of barrier functions in patients with 
high-grade gliomas (reviewed by Wolburg et al., 2012). Indeed, Wang and collaborators 
(2003) found a positive correlation between MMP-2 and MMP-9 expression and the 
different glioma WHO grades (I-IV). Using glioma tissue samples and by 
immunohistochemistry, the authors observed a weak expression of MMP-2 and MMP-9 
in low-grade malignant glioma, in contrarily to the high-grade malignant glioma which 
showed a strong expression of both MMPs (Wang et al., 2003). There are some 
glioblastomas clinical features, such as high aggressiveness that can be related with some 
changes in the BBB, but in contrast this increased permeability could facilitate the 
penetration of chemotherapeutic drugs into the tumor. However, there is no study clearly 
showing the BBB alterations in different tumor grades and even more important if these 
changes are sufficient to allow the entrance of antitumor drugs that usually do not cross 
the BBB. Of course that the success of this approach will always depend on the 
glioblastoma stage since the treatment of advanced tumor with a characteristic necrotic 
centre appears to come too late for the patient. 
Another clinical feature of the glioblastomas involves the intracerebral pressure 
due to edemas. Brain edema is an abnormal state that consists of an increase of brain 
water content. The water content is controlled by a family of water channels denominated 
aquaporins (AQPs), and the most expressed AQPs in the brain are type 1, 4 and 9. Brain 
edema can be generally divided in two types: cytotoxic and vasogenic edema (Figure 7). 
In cytotoxic edema occurs cell swelling, associated with a reduced brain extracellular 
space volume and intact BBB. Water flows from the vasculature into the intracellular 
brain compartment when the Na
+
/K
+
 ATPase fails or extracellular [Na
+
] falls. Under this 
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conditions water moves from the blood through endothelial cells and astrocyte foot 
process membrane, via AQP4, into brain. Usually, this type of edema is produced by 
early phase cerebral ischaemia, hypoxia and hyponatremia. In vasogenic edema, 
hydrostatic forces cause extravasation of a protein-rich exudate from plasma, through 
leaky BBB into brain extracellular space. Here, water moves from blood down a 
hydrostatic pressure gradient through a leaky BBB into brain extracellular space, and so 
independently of AQP4. Brain tumour and brain abscess produce vasogenic edema (Tait 
et al, 2008; reviewed by Francesca et al., 2010). Importantly, AQP4 was described 
several times to be up-regulated in brain tumors including glioblastomas (Saadoun et al., 
2002), and, another study showed that phosphorylation of AQP4 by PKC leads to a 
decrease in water permeability and a decreased in glioma cell invasion. On the other 
hand, when PKC was inhibited the water permeability increased, as well as cell invasion 
potential (McCoy et al., 2010). Also, it was shown that inhibition or silencing of AQP4 
cause a decreased in cell migration and its invasion ability (Ding et al., 2011). Under 
pathological conditions like tumor, inflammation or stroke, the AQP4-related polarity is 
reduced, which indicates the presence of potassium and water channels in physiologically 
unsuitable membrane domains.  
 
 
Figure 7 - Cytotoxic and Vasogenic Edema. A) Cytotoxic edema, where the increase in water 
brain content is dependent of astrocytic AQP activity. B) Vasogenic edema, in which water 
accumulation is independent of AQP (adapted from Tait et al, 2008).  
 
1.8. Methamphetamine 
 
       Methamphetamine (METH) is a drug that belongs to the amphetamine-type 
stimulants (ATS) family, along with amphetamine and ecstasy (or 3,4-
methylenedioxymethamphetamine, MDMA), which has great similarity with the 
neurotransmitter dopamine (Figure 9). METH has two isomers, d-methamphetamine 
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which is a common drug of abuse and l-methamphetamine, which has about 25-30% of 
CNS activity of its d-enantiomer  (Logan, 2002). Methamphetamine is highly addictive 
and toxic to the brain (Sulzer et al., 2005), and can be consumed in various ways such as 
smoked, injected, snorted and taken orally (Winslow et al., 2007; Nakama et al., 2008). 
     According to the United Nations World Drug Report 2012 the worldwide 
amphetamines consumption is between 14 and 52.5 million among people between 15 
and 64 years old, which represents 0.3% to 1.2% of annual prevalence, making METH 
one of the most widely used drug globally (United Nations Office on Drugs and Crime, 
2012) (Figure 8). Concerning Portugal, according to the report from the “Instituto da 
Droga e da Toxicodependência, IDT 2009”, between 2001 and 2007, there was an 
increase in prevalence of amphetamines use from 0.5% to 0.9% in the total population. 
More recently, data from the IDT report "Estudo sobre o Consumo de Álcool, Tabaco e 
Drogas (ECATD)/ European School Survey on Alcohol and other Drugs (ESPAD) - 
Portugal/2011", showed that between 2007 and 2011, there was an increase in prevalence 
of amphetamines from 0.3% to 2% in students between 13 and 18 years old. However, 
these reports include all the amphetamines, with the exception of ecstasy, and due to that 
there are no specific data on METH use. 
 
 
Figure 8 - Worldwide distribution of amphetamines use in 2010 (adapted from United Nations 
World Drug Report, 2012). 
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        METH has different effects depending if it is taken chronically or acutely. 
Immediately after consumption, METH leads to alertness, wakefulness, euphoria, 
increased activity (Quinton et al., 2006; Kish et al., 2008), hyperthermia, and decrease in 
appetite (Yamamoto et al., 2010). Moreover, at long-term use originates mood 
disturbances, confusion, anxiety, weight loss, insomnias, among others (Buchanan et al., 
2010). In fact, chronic METH abusers can experience psychotic and violent behavior, 
verbal learning and memory impairment, hallucinations, and even seizures (Quinton et 
al., 2006; Ramirez et al., 2009, Yamamoto et al., 2010; Buttner, 2011). 
 
 
Figure 9 - Chemical structure of methamphetamine and dopamine showing their similarities 
in blue (adapted from Fleckenstein et al., 2007).  
 
1.8.1. Neurotoxicity 
 
METH neurotoxicity has been characterized by the disruption of synaptic integrity 
of the dopaminergic system. This drug has the ability to increase neuronal release of 
monoamines, particularly the catecholamine dopamine (DA), which is the major 
neurotransmitter impacted by METH use. This occurs due to alterations in both the 
membrane dopamine transporter (DAT) and the vesicular monoamine transporter-2 
(VMAT-2) (Riddle et al., 2006). The function of VMAT-2 in normal cells is to sequester 
cytoplasmic DA into vesicles for storage and subsequent release. METH interferes with 
the function of VMAT-2, impairing its ability to store DA into vesicles (Fumagalli et al., 
1999; Fleckenstein et al., 2003). Additionally, under normal conditions, DAT clears 
extracellular DA from the synaptic cleft back into the nerve terminal. This reuptake of 
DA will further allow the storage of this neurotransmitter into synaptic vesicles via 
VMAT-2 for later release (Riddle et al., 2006).  
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When METH reaches the brain there is an increase in extracellular DA that leads 
to the formation of DA quinones and hydroxyl radicals which results in the production of 
reactive oxygen species (ROS) (Graham et al., 1978; Chiueh et al., 1993). Moreover, 
METH also increases the release of glutamate that in turn will increase intracellular 
calcium concentrations causing activation of nitric oxide synthase (NOS) and the 
consequent generation of reactive nitrogen species (RNS). In turn, ROS and RNS can 
alter proteins, lipids, and DNA, as well as inhibit mitochondrial function to produce 
energy deficits in the nerve terminals. This energy depletion may contribute for neuronal 
damage or even death (reviewed by Davidson et al., 2001). Alterations in neurons will 
then trigger a response by surrounding cells, such as microglia and astrocytes (Thomas et 
al., 2004) (Figure 10).  
These reactive glial cells may release several factors (e.g. TNF-α, NO) that usually 
aggravate the brain damage. Indeed, glial cells seem to be activated in response to 
METH, but its effects on microglial cells are not fully understood (Gonçalves et al., 2010, 
2012). In fact, animal studies, demonstrated that a single high dose of METH induces a 
neuroinflammatory response in mouse hippocampus, and this response was characterized 
by the activation of microglia and production of proinflammatory cytokines, namely 
TNF-α (Gonçalves et al., 2010). Nevertheless, it has been shown that cytokines, which 
are mainly released by activated microglia, may have a dual role in response to brain 
injury (Coelho-Santos, 2012). In vitro studies performed by the same group, showed that 
METH increased TNF-α and IL-6 levels, as well as their receptors protein levels. 
However, the endogenous proinflammatory cytokines did not contribute to METH-
induced microglial cell death. On the other hand, exogenous low concentrations of TNF-α 
or IL-6 demonstrated a protective effect. In the same study, it was also verified that the 
anti-apoptotic role of TNF-α was mediated by activation of IL-6 signaling, specifically 
the janus kinase (JAK)-STAT3 pathway, which in turn induced down-regulation of pro- 
and anti-apoptotic proteins (Coelho-Santos et al., 2012). 
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Figure 10- Mechanisms of METH neurotoxicity. METH enters in dopaminergic terminals (1), 
causing efflux of DA from intraneuronal vesicles. This DA is oxidized intracellularly, producing 
reactive species (2) such as hydrogen peroxide (H2O2) and superoxide (
.
O2
–
), and is transported to 
extracellular spaces (3) where it is also oxidized producing reactive oxygen species (ROS). High 
intracellular concentrations of DA and METH can inhibit the electron transport chain (ETC) in 
mitochondria (4), causing leakage of high-energy electrons which trigger the formation of 
superoxide. METH-induced increases in GLU release (5), stimulate NMDA receptors (NMDAR) 
on dopaminergic terminals to cause increases in intracellular Ca
2+
. These Ca
2+
 increases stimulate 
nitric oxide synthase (NOS) activity, increasing the production of nitric oxide (NO), which can 
combine with superoxide to form peroxynitrite (
.
ONOO
–
) (6). METH also stimulates microglia to 
release ROS and cytokines (8) which increase extracellular GLU levels. Finally, METH causes 
leakage of the BBB, allowing plasma proteins to enter the brain (9) (adapted from Marshall and 
O'Dell, 2012). 
 
Studies with human subjects have shown that METH chronic users demonstrate 
structural abnormalities in the brain, namely loss of grey matter, white matter hypertrophy 
and altered glucose metabolism in specific regions such as hippocampus, prefrontal 
cortex, cingulated gyrus and amygdale (Thompson et al., 2004). Additionally, data from 
animals show that a high dose of METH damages striatal dopamine nerve terminals 
(McCann et al., 2004). However, there is no evidence for dopamine nerve terminal 
damage in humans who take therapeutic doses of amphetamines (Ricaurte et al., 2005). 
Although METH can be abused, it can be also used for therapeutic purposes. Indeed, 
Desoxyn (Methamphetamine Hydrochloride) is a FDA approved drug marketed in USA 
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to treat attention-deficit hyperactivity disorder (ADHD). Furthermore, METH has been 
used in other human conditions beyond ADHD, such as mood disturbance (Hart et al., 
2005), eating disorders like bulimia nervosa (Drimmer, 2003), and in Parkinson’s disease 
(Devos et al., 2007; Moreau et al., 2012). 
 
1.9. Cell cycle and drugs 
 
 Cell division is mainly characterized by two consecutive processes, DNA 
replication and segregation of replicated chromosomes into two separated cells. Cell 
division can be divided into two stages: mitosis (M), the process of nuclear division; and 
interphase, the interval between two M phases. Mitosis stages include prophase, 
metaphase, anaphase and telophase. At interphase, cells grow in size and pass through G1, 
S and G2 phases. In S phase occurs the replication of DNA. Importantly, this phase is 
preceded by a gap, G1, during which the cell is preparing for DNA synthesis, and is 
followed by a second gap, G2, when the cell prepares for mitosis. G1, S, G2 and M phases 
are the traditional subdivisions of the standard cell cycle. Cells in G1 can, before start 
DNA replication, enter in a resting state called G0 (Figure 11). Cells in G0 account for the 
major part of the non-proliferating, non-growing cells in the human body (Reviewed by 
Vermeulen et al., 2003). 
 
 
Figure 11 - Cell cycle phases and their regulators: cyclins and cyclin dependent kinases (CDKs) 
(adapetd from Vermeulen et al., 2003). 
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 The cyclins and their catalytic associates, the cyclin dependent kinases (CDKs), 
are cell cycle regulators. Cyclins act in concert with their CDKs to drive cells from one 
phase of the cell cycle to the next (Gautschi et al., 2007), and different cyclins are 
required at different phases of the cell cycle (Figure 11). The three D type cyclins (cyclin 
D1, D2 and D3) bind to CDK4 or to CDK6, and CDK-cyclin D complexes are essential 
for entry in G1 phase. Unlike the other cyclins, cyclin D is not expressed periodically, but 
is synthesized as long as growth factor stimulation persists. Another G1 cyclin is the 
cyclin E, which associates with CDK2 to regulate progression from G1 into S phase 
(reviewed by Vermeulen et al., 2003). Cyclins D1 and E are involved in proliferation, 
apoptosis, invasion, differentiation and angiogenesis (Wang et al., 2012; Spruck et al., 
1999). In fact, these cyclins are considered to be key oncogenes and they are 
overexpressed in breast, liver, lung and brain cancers (Gillet et al., 1996; Hall et al., 
1996; Molenaar et al., 2008; Akli and Keyomarsi 2003). Regarding cyclin A, it binds to 
CDK2 and this complex is required during S phase. In late G2 and early M, the complex 
cyclin A-CDK1 promotes entry into M phase. In line with this, cyclin A overexpression 
has been found to be an adverse prognostic factor in non-small-cell lung cancer (Volm et 
al., 1997), breast cancer (Bukholm et al., 2001) and colorectal cancer (Handa et al., 
1999). In addition, expression of cyclin A has been found to be associated with a high 
malignancy potential in sarcomas (Huuhtanen et al., 1999) and prostate cancer (Aaltomaa 
et al., 1999). Mitosis is further regulated by cyclin B-CDK1 complex (reviewed by 
Vermeulen et al., 2003).  
 Cyclins expression could be altered by several drugs (Basso et al., 2002; Li et al., 
2000; Hashemolhosseini et al., 1998). DOX, MTX and METH are able to change cyclins 
expression or/and function and consequently deregulate cell cycle. Concerning cell cycle, 
METH down-regulates D1 and A1 gene expression in neuroblastoma cells (Bachmann et 
al., 2009). Recently, our group also demonstrated that METH delayed cell cycle in the 
G1-to-S phase transition, which was correlated with a decrease in cyclin E and pERK1/2 
protein levels in DG neurospheres (unpublished data). 
 MTX, as an antimetabolite that hind the biosynthesis of purines and thymidines 
(Boiardi et al., 1999) necessary for DNA and RNA synthesis, has a great influence in cell 
cycle. Some studies involving oral carcinomas cells, demonstrated that MTX treatment 
leads to a reduction of cyclin B1 expression (Pavelic et al., 2009) and to a cell cycle arrest 
at the S and G2 phases (Duran et al., 2001).The MTX-induced cell cycle arrest at S phase 
was also observed in primary cultured astrocytes (Bruce-Gregorios et al., 1991), 
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melanoma (Sáez-Ayala et al., 2012), osteosarcoma (Martins-Neves et al., 2012), 
leukemia (Tsurusawa et al., 1990) and breast cancer cells (Costantini et al., 2010). 
 It is known that DOX induces cellular apoptosis by intercalating into the DNA 
(Zhang et al., 2010) destabilizing the normal cell cycle. Studies involving glioma cells, 
showed that around 70% of the cells treated with DOX were in G0/G1 phase, which 
proves the DOX ability to inhibit cell cycle progression. This inhibition could also be 
related with the decrease of cyclin E protein expression that is required for the cell cycle 
progression into the S phase (Gopinath et al., 2009). DOX has a similar effect in human 
colon cancer cells, arresting cells in G0/G1 phase (Lupertz et al., 2010). However, in 
human breast carcinoma cells (Kuznetsov et al., 2011), osteosarcoma cells (Martins-
Neves et al., 2012) and bladder cells (Bilim et al., 2000) treated with DOX showed a 
significant increase in cells arrested in the G2/M phase of the cell cycle.  
1.10. Methamphetamine and Blood-Brain Barrier 
 
There are several studies showing that METH can lead to BBB disruption. Animal 
studies demonstrated that mice administered with an acute high dose of METH show an 
increase in BBB permeability in the medial and ventral amygdala, hippocampus (Martins 
et al., 2011; Bowyer and Ali, 2006) caudate-putamen (Bowyer et al., 2008) and striatum 
(Urrutia et al., 2013). Moreover, in vitro studies published by Mahajan and others (2008) 
demonstrated that METH alters the BBB function through direct effects on endothelial 
cells, specifically by modulating the expression of tight junction proteins, and also by 
enhancing the production of reactive oxygen species (Ramirez et al., 2009). More 
recently, it was demonstrated that METH transiently increases BBB permeability in the 
hippocampus due to a downregulation of the TJ proteins, namely ZO-1, claudin-5 and 
occludin, which may be also correlated with the increase in MMP-9 activity and 
expression by hippocampal neurons (Martins et al, 2011). Additionally, it was 
demonstrated that the decrease in BBB integrity in the stratum induced by METH was 
mediated by the JNK pathway, which activates MMP-9 causing degradation of laminin 
and BBB leakage (Urrutia et al., 2013). Other explanation for METH-induced BBB 
permeability was raised by Park and collaborators (2011) by demonstrating the activation 
of a NOX complex and caveolae-associated pathways that resulted in the generation of 
ROS and alterations of occludin protein levels. Recently, our group showed that the 
increased in endothelial cells permeability triggered by METH involves eNOS/NO-
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mediated transcytosis (Martins et al., 2013). Additionally, METH also seems to interfere 
with the glucose uptake by endothelium cells compromising the BBB normal function. 
Studies conducted by Abdul Muneer et al. (2011) demonstrated that an impairment of 
GLUT1 at the brain endothelium by METH may contribute to energy-associated 
disruption of tight junction assembly and loss of BBB integrity. 
It is worthwhile to point out that METH-induced BBB permeability could be 
considered an useful approach to allow the passage across BBB of drugs that could have a 
potential therapeutic effect in brain diseases, such as chronic myelogenous leukaemia and 
glioblastoma (Kast, 2009; Kast and Focosi, 2010). In clinics, METH is successfully used 
to treat attention-deficit hyperactivity disorder, mood disturbance (Hart et al., 2005) and 
eating disorders (Drimmer, 2003), as it was mentioned previously. This drug is, in 
general, well tolerated with low risk of abuse in this patient’s and could be easily 
administered to normal or medically ill and frail patients. Methamphetamine’s high doses 
and long term use should be avoided due to its addictive and neurotoxic potential. 
Nevertheless, it has been discussed that risks of low doses and short-term use of METH 
are low and well known by the physicians. So, under conditions of brain tumors the 
severity of CNS malignancy is such that the small risks of METH use could be justifiable 
(Kast, 2007). Importantly, METH ability to generate reversible disruption of BBB in 
rodents, adding to no evidence of brain damage in humans who take therapeutic doses of 
amphetamines and the pharmaceutical circulating half-life of 9 to15 hours, Cmax of 1 hour 
(Kast and Focosi, 2010), can support the use of METH to open the BBB during 
intravenous or oral administration of MTX or DOX to allow the entrance of these 
chemotherapeutic drugs into the brain. 
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CHAPTER 2 
Material and Methods 
 
2.1. Cell culture 
 
 The human glioblastoma cell line U-118MG (American Type Culture Collection, Manasas, 
VA, USA) was cultured in Dulbecco’s modified essential medium (DMEM) high glucose (4 g/L; 
Gibco, Scotland, UK) supplemmented with 10% fetal calf serum (FBS; Gibco), 3.7 g/L sodium 
bicarbonate (Sigma-Aldrich, St. Louis, MO, USA), 100 U/mL penicillin and 100 μg/mL 
streptomycin (Gibco), at pH 7.4. Cells were maintained in a humidified atmosphere with 5% CO2, at 
37°C, and were discarded after 40 passages. 
 
 2.2. MTT assay 
 
 The effects of METH and of chemotherapeutic agents (DOX, MTX and TMZ) on U118 cells 
were analyzed using the [3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide] (MTT) 
colorimetric assay. This method is based on the enzyme mitochondrial dehidrogenase NADH 
activity which is active only in viable metabolically active cells. This enzyme reduces the yellow 
tetrazolicum salt converting it in insoluble purple crystals (formazan crystals). Formazan crystals can 
be quantified by spectrophotometry where the resultant intensity is proportional to the enzyme 
activity and, consequently, to the viable cells number.   
 U118 cells at a confluence of 70% were harvested and seeded in 96 multiwell plates at a 
density of 150 000 cells/well in 100 µL and allowed to attach overnight. Then, cells were treated 
with METH or/and anti-tumoral drugs as follows (in µM): METH (Methamphetamine 
hydrochloride, Sigma, USA) - 0.01, 1, 10, 100, 500, 650, 850, 1000 µM; DOX (DOXO-cell®, 
Portugal) - 0.001, 0.01, 0.25, 0.5, 1, 5, 10, 50, 100; MTX (Teva Pharma, Portugal) - 0.001, 0.01, 
0.025, 0.05, 0.075, 0.1, 1, 10, 100, 1000; and TMZ (Sigma Chemicals, St. Louis, MO, USA) - 0.01, 
1, 10, 25, 50, 75, 100, 250, 500, 1000. After 48 h of drug exposure, cells were washed with Krebs 
solution [142 mM NaCl, 4 mM KCl, 1 mM MgCl, 1 mM CaCl, 10 mM Glucose, 10 mM HEPES  pH 
7.4], and 0.5 mg/mL MTT (Sigma) solution was added to each well and incubated at 37 °C, for 1 h, 
protected from light. The formazan crystals were vigorously dissolved with 0.04 M isopropanol-HCl 
(50 μl per well). Absorbance was measured at 570 nm (reference 620 nm) using the SynergyTM HT 
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multi-detection microplate reader (BioTek, Windoski, USA). The results were expressed as 
percentage of control and the IC50 values (concentration of drug that reduces cell survival by 50%) 
were calculated using non-linear regression analysis (GraphPad Prism).  
 
2.3. Migration assay 
 
 U-118 cells were seeded in 12-well plates at a density of 200 000 cells/ well and allowed to 
attach overnight. Then, cells were treated for 24 h with DOX (0.25 μM) or MTX (0.01 μM) alone or 
plus METH (1 μM). When plates were confluent, the cell monolayer was scraped in a straight line 
with a small tip, culture medium was removed in order to clean debris, and new culture medium was 
added. The plate was observed under the phase-contrast microscope and an image from each well 
was acquired at 0 h, 4 h, 8 h, 24 h, 28 h, 32 h and 48 h, after the scratch was done. Migration was 
evaluated using a homemade MATLAB-based software (Matlab®). Briefly, for each condition, all 
images were filtered with an adaptive filter to smooth the image while preserving the edges, and then 
a region of interest was drawn in the first image, which was used as reference (0h) Afterwards, the 
algorithm analyze the other images obtained at different time points by measuring the signal in the 
region defined by the user, and consequently the level of cell migration. Each experiment was 
repeated six times. 
 
2.4. Chemotaxis assay  
 
 Chemotaxis assay was carried out using HTS 96 transwell permeable supports with 8 µm 
pores (Corning, NY, USA). Cells were starved for 24 h, resuspended in Krebs solution and plated in 
the transwell (upper chamber). CXCL12 (Peprotech, Rocky Hill, NJ, USA) (100 ng/mL) was added 
to the medium in the lower chamber. Cells were treated with DOX (0.25 μM) or MTX (0.01 μM) 
alone or plus METH (1 μM) at 37ºC in a 5% CO2 incubator for 12h. At least one well per experience 
was used as blank (with no cells) and as a control without CXCL12. After this period, calcein-AM 
(Invitrogen) (0.002 µg/µL) was added to the lower chamber, at 37ºC for 1 h, followed by 
fluorescence measurement at 485 nm and 528 nm (excitation and  emission, respectively) using the 
SynergyTM HT multi-detection microplate reader (BioTek, Windoski, USA) (Figure 12).  
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Figure 12 - Schematic representation of the chemotaxis assay using HTS 96 transwell permeable 
support. U-118 cells were seeded into the upper chamber, while CXCL12 was added into the lower chamber. 
The chamber was incubated at 37° C, 5% CO2. After 12 hours of incubation, invasive cells that passed 
through the membrane were labeled with calcein-AM. After 1h of incubation, the fluorescence was measured.  
The percentage of invaded cells was calculated using a standard curve performed before the assay. 
 
 A standard curve was performed for each assay (cells/well: 50000, 25000, 12500, 6250, 3125, 
1562.5, 781.25, 0). A volume of 50 µl from dilution was added in triplicate to a well from a 96-well 
solid black microplate. Additionally, 50 µl of calcein AM (0.002 µg/µL) was added to each well of 
the standard curve. The plate was incubated for 1 h in the dark at room temperature then read using 
the fluorescence top reader option in the SynergyTM HT multi-detection microplate reader (485 nm 
and 528 nm, excitation and emission, respectively). The obtained relative fluorescence units (RFU) 
values for each concentration were averaged and then background (no cells) was subtracted.  
 The total number of cells that passed through the membrane of each well was calculated as 
shown in the equation: 
% Invasion ൌ Cell concentrationInicial cell seeded ൈ 100 
 
2.5. Flow cytometry  
 
 Cells were plated in 12-well plates at a density of 300 000 cells/well and allowed to attach 
overnight. Then, cells were treated with DOX (0.25 μM) or MTX (0.01 μM) alone or plus METH (1 
μM) for 24h or 48h, Afterwards, cells were centrifuged at 132 xg for 5 min, the culture medium was 
discarded and the pellet was resuspended in a solution of 75% ethanol and maintained overnight at 
4°C. Fixed cells were then centrifuged at 206 xg for 20 min, the pellet was resuspended and 
incubated for 1 h 15 min in the dark at RT in a solution of 1x PBS containing 10 μl/ml propidium 
iodide (PI, Invitrogen, Paisley, UK) and 500 μg/ml RNAse (Sigma). The PI fluorescence was 
measured on a FACScan flow cytometer (BD FACSCalibur™) and the data were gated to exclude 
cell debris and aggregates by using the software ModFit LT™ 3.0. For each sample were acquired 
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2x10
4
 events. 
2.6. Western blot 
 
 Glioblastoma cells were seeded in six-well plates at a density of 350 000 cells/mL, and when 
70% confluence was reached, cells were treated with DOX (0.25 μM) or MTX (0.01 μM) alone or 
plus METH (1 μM) for 48h. Cytosolic fraction was obtain by lysing the cells using a buffer solution 
composed by 10 mM HEPES (pH 7.9), 10 mM KCl, 0.1 mM EDTA (Ethylenediamine tetraacetic 
acid), 0.4% NP-40 and 1 mM dithiothreitol (DTT) (Bioron, Porto, Portugal), supplemented with 
protease inhibitor cocktail tablets (Roche, Indianapolis, IN, USA). Lysates were placed on ice for 30 
min and centrifuged at 16000 xg, at 4°C for 7 min. The supernatant (cytosolic fraction) was collected 
and the pellet was washed with 1 ml 1x PBS (Phosphate Buffered Saline) and centrifuged at top 
speed for 1 min. Nuclear fraction was obtain by resuspending the pellet using a buffer solution 
composed by 20 mM HEPES (pH 7.9), 0.4 M NaCl, 1 mM EDTA, 10% glycerol and 1 mM 
dithiothreitol (DTT) supplemented with inhibitor cocktail tablets. The resuspension was placed on 
ice for 1h, sonicated and centrifuged at 16000 xg, at 4°C, for 7 min. The supernatant was saved and 
pellet was discarded. Protein quantification was performed using the bicinchoninic acid (BCA) 
method (Pierce, Rockford, USA) with BSA as a standard. Cytosolic fraction was stored at -20°C and 
nuclear fraction at -80°C until further use. Protein samples were prepared under reduced conditions 
by adding sample buffer (0.5 M Tris-HCl, 4% SDS, 30% glycerol, 10% SDS, 0.6 M DTT, 
bromophenol blue; pH 6.8) and heating at 95°C for 5 min. Proteins (Table 1) were separated by 
electrophoresis on 12% polyacrylamide gels at 160 V and transferred to polyvinylidene fluoride 
(PVDF) membranes (Millipore, Madrid, Spain) that were blocked with 5% (w/v) low fat milk in 
PBS-T [PBS containing 0.1% (v/v) Tween-20 (Sigma)]. Then, membranes were incubated overnight 
at 4°C with primary antibodies as described in Table 3. After washing with PBS-T during 30 min, 
membranes were incubated with the respective alkaline phosphatase-conjugated secondary antibody 
(anti-mouse 1:10000 or anti-rabbit 1:20000) (Amersham GE Healthcare Life Science, USA), for 1 h, 
at RT. The membranes were again washed with PBS-T, and bands were visualized, using the 
enhanced chemiofluorescence (ECF) reagent (Amersham), on the Typhoon FLA 9000 (GE 
Healthcare Bioscience AB, Uppsala, Sweden). To ensure equal sample loading, glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) antibody was used in cytosolic fraction samples and lamin B 
antibody was used in nuclear fraction samples (Table 2). Quantification of band density was 
performed using ImageQuant 5.0 software. 
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Table 2 – List of proteins identified by western blot analysis. 
Protein Molecular weight (kDa) Amount of protein (μg) 
 
  Cyclin D1 
 
36 
 
25 
Cyclin A 60 25 
Lamin B  66 25 
GAPDH 37 25 
 
 
Table 3 - List of primary and secondary antibodies used in western blot studies. 
Primary 
antibody 
Dilution Source Secondary antibody Dilution Source 
Mouse anti-
cyclin D1 
1:100 Santa Cruz 
Biotechnology 
Anti-mouse IgG 
alkaline phosphatase 
conjugated 
 
1:10000 Amersham GE 
Healthcare Life 
Science  
Mouse anti-
cyclin A 
1:200 Abcam 
 
Anti-mouse IgG 
alkaline phosphatase 
conjugated 
 
1:10000 Amersham GE 
Healthcare Life 
Science  
Rabbit anti-
lamin B 
1:1000 Abcam Anti-rabbit IgG 
alkaline phosphatase 
conjugated 
 
1:20000 Amersham GE 
Healthcare Life 
Science  
Mouse anti-
GAPDH 
1:1000 Abcam Anti-mouse IgG 
alkaline phosphatase 
conjugated 
1:10000 Amersham GE 
Healthcare Life 
Science  
  
 
 
2.7. Statistical analysis 
 
 Statistical analysis was performed using GraphPad Prism 5.0 (GraphPad Software, San 
Diego, CA). Data was analyzed using the one-way ANOVA analysis of variance followed by 
Dunnett’s post hoc to compare experimental conditions with control. Data were considered to be 
statistical different at values of P<0.05 and were presented as means + SEM (standard error of the 
mean). 
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 In cell cycle and migration studies, data were analyzed using an unpaired one tailed Mann-
Whitney test or one-way ANOVA analysis of variance followed Bonferroni’s post hoc to compare 
differences between experimental conditions. 
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CHAPTER 3 
Results 
 
Effect of methamphetamine and chemotherapeutic drugs on:  
3.1. Glioblastoma cell viability 
 
 In the present study our main goal was to evaluate the possible effect of METH as a co-
adjuvant for chemotherapeutic drugs, specifically as a toll to transiently open the BBB. So, we 
started by analyzing the effect of METH on cell viability, and for that, we used the MTT assay. 
METH induced a significant decrease in U-118 cell viability for a drug concentration equal and 
above 650 μM (Figure 13; control: 100.0+5.3%; METH: 0.01 µM, 97.9+5.6%; 1 µM, 101.9+9.1%; 
10 µM, 97.5+9.8%; 100 µM, 95.2+6.7%; 500 µM, 82.0+4.2%; 650 µM, 74.8+6.6%; 850 µM, 
51.1+6.4%; 1000 µM, 0.9+0.2%).  
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Figure 13- Effect of METH on glioblastoma cell viability. U-118 cells were exposed to increasing METH 
concentrations (0.01–1000 µM) for 48 h. Cell viability significantly decreased at a concentration equal or 
above 650 µM METH. The results are expressed as mean % of control + SEM, n=4 performed in triplicate. 
*P <0.05,***P <0.001, significantly different when compared to the control using one way ANOVA followed 
by Dunnett’s Multiple comparison test. 
 
 For this work we were particularly interested in identify a non-toxic concentration of METH, 
e.g. that could increase endothelial cells permeability without leading to cell death. In fact, a 
previous work by our group showed that 1 µM METH increases endothelial cell permeability, 
without affecting cell viability (Martins et al., 2011). Additionally, we also know that METH at low 
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concentrations can increase cell proliferation (Coelho-Santos et al., 2012). So, based on our previous 
studies and in our results (Figure 13), we decided to use 1 μM METH in the following studies. 
 MTX is a chemotherapeutic agent that is widely used in pediatric neuro-oncology and 
function as a folate antagonist with a potential effect against malignant gliomas (Wolff et al., 1999, 
2011). DOX has also been demonstrated to have a cytotoxic activity against highly invasive human 
glioblastoma cell lines (Nabissi et al., 2013). However, unlike TMZ that crosses the BBB, these 
chemotherapeutic drugs have limited penetration into the brain. Thus, the transient opening of BBB 
induced by METH (Martins et al., 2011, 2013) could be considered an useful therapeutic approach to 
allow the entrance of these drugs. To explore this idea, we further evaluated U-118 cell viability in 
the presence of DOX or MTX alone or in the presence of METH. Cells were treated with different 
concentrations of DOX (0.001, 0.01, 0.25, 0.5, 1, 5, 10, 50, 100 μM) for 48h and it was observed a 
concentration-dependent decrease in cell viability (Figure 14). Moreover, METH did not 
significantly interfere with the effect of DOX alone (Table 4, Figure 14) and, indeed, the IC50 values 
were very similar (DOX: 0.23±0.05 μM; DOX+METH: 0.21±0.07 μM) (Table 6). 
Table 4 - Effect of DOX and DOX plus METH (1µM) on glioblastoma cell viability.  
 Cell viability (% of control) 
[DOX] (µM) DOX DOX+METH 
0 
100±7.8 100±2.9 
0.001 
99.2± 9.5 110.0±8.7 
0.01 
97.8±9.6 109.6±8.7 
0.1 
77.5±14.1 86.8±8.2 
0.25 
52.3±13.4 42.1±15.2 
0.5 
13.2±2.5 13.6±3.5 
1 
7.8±3.4 6.8±2.6 
5 
0.6±0.4 0.5±0.2 
10 
0.6±0.3 0.4±0.2 
50 
0.8±0.5 0.5±0.2 
100 
1.1±0.7 0.7±0.2 
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Figure 14 - Effect of DOX and DOX plus METH (1 µM) on glioblastoma cell viability.  U-118 cells were 
treated for 48 h with increasing concentrations of DOX (0.001, 0.01, 0.25, 0.5, 1, 5, 10, 50, 100 μM) or in 
combination with 1 μM METH. Cell viability was determined by MTT assay. Data are expressed as mean ± 
SEM and were fitted to a sigmoid function for IC50 calculation; n=6, performed in triplicate.  
 
 As above mentioned for DOX, U-118 cells were also treated with MTX (0.001, 0.01, 0.025, 
0.05, 0.075, 0.1, 1, 10, 100, 1000 μM), which induced a decrease in cell viability in a concentration-
dependent manner (Table 5, Figure 15). No significant differences between MTX alone and 
MTX+METH were observed (Table 6: IC50 values – MTX: 0.01+0.005 μM; MTX+METH: 
0.01+0.001 μM).  
Table 5- Effect of MTX and MTX plus METH (1µM) on glioblastoma cell viability.  
 Cell viability (% of control) 
[MTX] (µM) MTX MTX+METH 
0 100±5.5 100±4 
0.001 100.3±7.4 103.1±7.2 
0.01 54.7±15.1 53.2±5.5 
0.025 26.8±6.5 27.7±3.4 
0.05 17.1±3.6 17.5±2.9 
0.075 11.8±4.5 11.2±2.7 
0.1 10.2±4.3 9.4±2.4 
1 8.7±2.2 7.6±2.1 
10 6.8±2.1 5.1±1.3 
100 5.8±2 4.5±1.7 
1000 4.8±2 4.1±1.5 
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Figure 15 - Effect of MTX and MTX plus METH (1µM) on glioblastoma cell viability. U-118 cells were 
treated for 48 h with different concentrations of MTX alone (0.001, 0.01, 0.025, 0.05, 0.075, 0.1, 1, 10, 100, 
1000 μM) or in combination with 1 μM METH. Cell viability was determined by MTT assay. Data are 
expressed as mean ± SEM and were fitted to a sigmoid function for IC50 calculation; n=5, performed in 
triplicate.  
 
Table 6 - IC50 values obtained by MTT assay after 48h of drugs exposure.  
 
Drug(s) IC50 (µM) 
DOX 0.23 ± 0.02 (n=6) 
DOX+METH 0.21 ± 0.04 (n=4) 
MTX 0.01 ± 0.002 (n=5) 
MTX+METH 0.01 ± 0.0004 (n=4) 
 
 
 TMZ is widely used in standard chemotherapy in clinics but still has some limitations 
(reviewed by Chamberlain, 2010). Here, we also evaluated its effect on U-118 cell viability (Figure 
16) and a significant decrease was observed only for concentrations above 500 μM, indicating that 
U-118 cells are highly resistant to TMZ. Additionally, METH, as previously observed with DOX and 
MTX, did not significantly interfere with the cytotoxicity of TMZ in U-118 cells (Table 7, Figure 
16).  
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Table 7 - Effect of TMZ and TMZ plus METH (1µM) on glioblastoma cell viability. 
 
 Cell viability (% of control) 
[TMZ] (µM) TMZ TMZ+METH 
0 100.0+3.7 100.0+1.4 
 
0.01 103.7+3.2 96.8+5 
1 109.3+2.1 108.0+3.1 
 
10 102.6+3.6 101.7+4.3 
25 100.1+2.2 100.5+4.6 
 
50 102.1+2 102.6+4.6 
75 101.4+2.4 101.8+6.2 
100 91.45+4.1 99.7+5.6 
250 92.37+3.2 93.6+5.2 
500 59.14+2.9*** 73.8+7** 
1000 25.94+2.2*** 41.1+6.5*** 
 
Data shown are expressed as mean + SEM, n=3 performed in triplicate. **P< 0.01,***P<0.001, significantly 
different when compared to the respective control (untreated cells) using one way ANOVA followed by 
Dunnett’s Multiple comparison test. 
 
 
Figure 16 - Effect of TMZ and TMZ plus METH (1µM) on glioblastoma cell viability. U-118 cells were 
treated for 48 h with different concentrations of (A) TMZ (0.01, 1, 10, 25, 50, 75, 100, 250, 500, 1000 μM) or 
in combination with (B) METH (1 μM). Cell viability was determined by MTT assay. Data shown are 
expressed as mean + SEM, n=3 performed in triplicate.**P< 0.01,***P<0.001, significantly different when 
compared to the control using one way ANOVA followed by Dunnett’s Multiple comparison test. 
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3.2. Glioblastoma cell migration 
 
 Glioblastoma is characterized by its aggressive behavior and high recurrence rate mainly 
because of its ability to migrate and invade other brain tissues (reviewed by Furnari et al., 2007). 
Taking this into consideration, we evaluated the effects of 1 µM METH alone and in combination 
with 0.25 µM DOX or 0.01 µM MTX in the migration of U-118 cells by using a scratch assay. The 
tested concentrations of DOX and MTX correspond to the respective IC50, obtained from previous 
studies. The results indicate that DOX or MTX impairs cell migration, whereas METH did not have 
any effect by itself and also did not interfere with the effect induced by DOX or MTX (Figure 17). 
 
Figure 17- Effect of 24 h treatment with 1 µM METH, 0.25 µM DOX, DOX plus METH, 0.01 µM MTX 
or MTX plus METH in cell migration, using a scratch assay. Representative images were taken at 
different time points as follows: starting point, t0h; after 8h, t8h; 24h, t24h; and 48h, t48h. Migration of cells 
resulted in an increased signal intensity into the scratch. Magnification x10. 
 
 Glioblastoma cell migration was quantified by using homemade based-Matlab® software. It 
was possible to observe that 1 µM METH did not significantly interfere with cell migration at all the 
time points analyzed (Figure 18, Table 8). However, a significant alteration in glioblastoma cell 
migration ability was observed in the presence of chemotherapeutic drugs, as demonstrated by the 
significant reduction in the signal intensity into the scratch (Figure 18, Table 8). This effect was not 
modified by METH. 
 
Table 8 - Quantification of signal intensity in the scratch under different drug(s) treatment(s). 
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Time  CTR METH DOX DOX+METH MTX MTX+METH 
0 h 0+0 0+0 0+0 0+0 0+0 0+0 
4 h 1753+573 1945+388 1323+483 1773+527 1298+386 1500+419 
8 h 3850+922 3886+767 2608+853 2880+735 2130+820 1864+414 
24 h 5873+1196 5695+1109 3130+957 2826+597 2391+690* 2277+488* 
28 h 7282+1842 6970+1655 3579+1041* 3287+443* 3177+771* 2822+548* 
32 h 7686+1998 6942+1679 3628+1094* 3104+495* 3179+924* 2794+655* 
48 h 9386+2166 8928+2043 3375+1316* 3919+888 5667+1295 4800+1472 
 
Data shown are expressed as mean + SEM, n=12. *P<0.05, significantly different when compared to the 
control at the same time-point using one way ANOVA followed by Dunnett’s multiple comparison test. 
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Figure 18 - Quantification of cell intensity in the scratch field using the home-made based-Matlab® 
software. Intensity difference is directly proportional to the number of cells that migrated into the scratch. 
Data shown are expressed as mean + SEM, n=12. *P<0.05, significantly different when compared to the 
control at the same time-point using one way ANOVA followed by Dunnett’s multiple comparison test. 
 
 
3.3. Glioblastoma cell chemotaxis 
 
 Previous studies showed that glioblastoma robustly express CXCR4, a chemokine stromal-
derived factor-1 (SDF-1 or CXCL12) receptor, and demonstrated a relationship between expression 
levels of the CXCR4 receptor and the infiltrative extension and growth of the tumor (Maru et al., 
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2008; Liu et al., 2010, Bian et al., 2007). Here, we also aimed to evaluate the chemotactic activity of 
U-118 cells treated with 1 µM METH, 0.25 µM DOX, DOX plus METH, 0.01 µM MTX or MTX 
plus METH. The results indicate that U-118 glioblastoma cells chemotactic ability was significantly 
increased in the presence of CXCL12 (control:89.8+8.9%; - CXCL12: 3.7+0.55%, ***P <0.001) 
(Figure 19). Furthermore, the chemotactic ability of glioblastoma cells was significantly decreased in 
the presence of METH, DOX or MTX when compared to the control (control: 89.8+8.9%; METH: 
66.3+3.2%, **P <0.01; DOX: 58.8+4.3%, ***P <0.001; MTX: 62.2+4 %, ***P <0.001) (Figure 7). 
Additionally, METH did not interfere with the chemotactic ability of DOX or MTX (DOX+METH: 
56.8+3.7%; MTX+METH: 64.7+4 %). 
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Figure 19 - Effect of METH (1 µM), DOX (0.25 µM), DOX plus METH, MTX (0.01 µM) or MTX plus 
METH on the chemotactic migration of U-118 glioblastoma cells. The results are expressed as mean % of 
control + SEM, n=4 performed in quadruplicate. **P<0.01, ***P<0.001 significantly different when 
compared to the control using one way ANOVA followed by Dunnett’s Multiple comparison test. 
 
3.4. Glioblastoma cell cycle 
 
 In previous studies it was observed that DOX alter the cell cycle of some types of malignant 
cells such as glioblastoma, breast carcinoma and colon cancer cells (Gopinath et al., 2009, 
Kuznetsov et al., 2011, Lupertz et al., 2010). MTX also induce cell cycle alterations in melanoma, 
osteosarcoma and leukemia cells (Sáez-Ayala et al., 2012, Martins-Neves et al. 2012, Costantini et 
al., 2010). Additionally, we recently showed that METH interferes with the cell cycle in 
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hippocampal stem cells (unpublished data). So, in the present study we evaluated the effect of the 
different drugs and combinations on U-118 cell cycle. 
 The cell cycle of untreated cells was characterized by a long and well-defined G0/G1 peak, 
with a slightly prominent G2/M peak (Figure 20). METH by itself did not significantly interfere with 
cell cycle, neither at 24 h nor at 48 h (Figure 20 and 21; Table 9). Treatment with 0.25 µM DOX for 
24 h induced a decrease in the percentage of U-118 cells into the S phase (25.6+3%) and a 
significant increase in the number of cells in the G2/M phase (19.2+3.3%,*P <0.05) relatively to 
untreated cells (S: 36.8+2.1%; G2/M: 6.1+0.6%). The cell cycle arrest at G2/M phase (18.6+4.7%, 
**P <0.01) together with a lower percentage of cells in S phase (24.5+2%) was maintained after 48h 
exposure to DOX. Co-incubation with METH did not induce significant alterations in the cell cycle 
progression neither at 24 h nor at 48 h, comparatively to cells treated with DOX alone. 
 Regarding MTX, 24 h exposure to this drug induced an arrest of U-118 cells in S phase 
(control: 36.8+2.1%; MTX: 67.7+12%, *P <0.05) and a decrease in G0/G1 phase (control: 
57.3+2.5%; MTX: 30.3+11%) when compared to the control. At 48 h, even though there is a small 
increase in percentage of cells in G2/M phase the difference was not significant (control: 4.9+1.4%; 
MTX:3.3+0.1%; Table 9). Once again, METH treatment did not induce significant alterations in the 
cell cycle progression neither at 24 h nor at 48 h, comparatively to cells treated with MTX alone 
(Figure 20 and 21; Table 9). 
 
 
Figure 20 - Representative histograms of U-118 cell cycle after 24 h and 48 h of incubation with  METH 
(1 µM), DOX (0.25 µM), DOX plus METH, MTX (0.01 µM) or MTX plus METH. Cell cycle analysis 
was performed by flow cytometry using propidium iodide (PI). A total of 20 000 events were analyzed for 
each experiment, n=3. 
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Table 9 - Quantitative analysis of the cell cycle distribution after 24 h and 48 h of U-118 cells incubation 
with METH (1 µM), DOX (0.25 µM), DOX plus METH, MTX (0.01 µM) or MTX plus METH. 
 
 G0/G1 phase S phase G2/M phase 
24 h 48 h 24 h 48 h 24 h 48 h 
CTR 57.3+2.5% 59+4.3% 36.8+2.1% 36+3.3% 6.1+0.6% 4.9+1.4% 
METH 56.1+2.9% 59.41+2.9% 39.1+3% 35.9+2.4% 4.6+0.2% 4.7+1.3% 
DOX 55.2+3.8% 56.9+3.9% 25.6+3% 24.5+2% 19.16+3.3%* 18.6+4.7%** 
DOX+METH 55.5+3.6% 59+3.2% 25+1.4% 23.8+2.5% 19.6+2.8%* 17.2+3.8%** 
MTX 30.3+11% 31.5+2.6%** 67.7+12%* 65.2+2.5%*** 2+1% 3.3+0.1% 
MTX+METH 29.8+13.3% 25.7+6.3%** 68.9+14%* 70.6+6.7%*** 1.4+0.7% 3.8+0.5% 
 
The results are expressed as mean % of total cells + SEM, n=3. *P<0.05, **P<0.01, ***P<0.001, 
significantly different when compared to the control using one way ANOVA followed by Dunnett’s Multiple 
comparison test. 
 
 
 
Figure 21 - Quantitative analysis of the cell cycle distribution, after (A) 24 h and (B) 48 h of U-118 cells 
incubation with METH (1 µM), DOX (0.25 µM), DOX plus METH, MTX (0.01 µM) or MTX plus 
METH. The results are expressed as mean % of total cells + SEM, n=3. *P <0.05, **P <0.01, ***P <0.001, 
significantly different when compared to the control using one way ANOVA followed by Dunnett’s Multiple 
comparison test. 
 
 Cell cycle is regulated by several cyclins that act in concert with their cyclin dependent 
kinases to drive cells through the different phases of the cell cycle (Gautschi et al., 2007). Here, we 
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evaluated the expression of cyclin A, a critical regulator of the S/G2 transition and G2/M phase 
checkpoint (Figure 22 A). METH (1 μM) did not alter cyclin A protein levels (90.9+3.6%), but DOX 
(0.25 μM) significantly decrease its protein levels (71.1+4.9% **P <0.01; Figure 22 A) compared to 
the control (100.0+5.5%), an effect that was not altered by METH (METH+DOX, 76.3+6.7%). 
Moreover, 0.01 μM MTX (83.7+10.4%) or MTX+METH (108.0+3.7%) had no significant effect. 
These results are in agreement with cell cycle arrest in G2/M phase that was observed in cells treated 
with 0.25 µM DOX or DOX plus METH. Additionally, the expression of cyclin D1, a protein 
responsible for the G0/G1 phase progression, was also evaluated (Figure 22 B). However, no 
significant alterations were observed with all the drugs studied (Figure 22 B - control: 100.0+10.3%; 
1 µM METH: 89.6+9.2%; 0.25 µM DOX: 83.3+6.8%; DOX+METH: 81.9+7.2%; 0.01 µM MTX: 
79.7+3.7%; MTX+METH: 93.2+8.4%).  
 
  
Figure 22- Effect of 48 h treatment with METH (1 µM), DOX (0.25 µM), DOX plus METH, MTX 
(0.01 µM) and MTX plus METH on the expression of (A) cyclin A and (B) cyclin D1 in U-118 
glioblastoma cells. Above the bars, representative western blot images of cyclin A (60 kDa), cyclin D1 (36 
kDa) and GAPDH (37 kDa) are shown. The results are expressed as mean % of control+SEM, n=8 (cyclin A) 
and n=5 (cyclin D1). *P< 0.05, **P< 0.01 significantly different when compared to the control using one way 
ANOVA followed by Dunnett’s Multiple comparison test.  
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CHAPTER 4 
Discussion 
 
 Glioblastoma multiforme is the most common and aggressive type of astrocytoma. 
Despite recent therapeutic advances, the median survival time for glioblastoma patients 
remains short. Among several factors that contribute to the reduced efficacy of treatment 
in glioblastoma, the  blood-brain barrier is one of the most relevant since it limits the 
delivery of standard chemotherapeutic agents. Taking this into consideration, it was 
hypothesized if the transient opening of BBB induced by METH (Martins et al., 2011, 
2013) could be considered an useful therapeutic approach to allow the entrance of 
chemotherapeutic drugs, such as MTX (Wolff et al., 1999, 2011) and DOX (Nabissi et 
al., 2013). Indeed, these two drugs are successfully used in other type of cancers. 
4.1. Effects of methamphetamine and chemotherapeutic drugs on 
glioblastoma cell viability 
 
 In attempt to clarify our hypothesis, we started to evaluate the direct effect of 
METH on glioblastoma cell viability. Our results showed that METH reduced U-118 
glioblastoma cell viability only for higher concentrations above 650 μM. Previous studies 
performed in our lab with primary cultures of astrocytes (unpublished data) demonstrated 
that METH is also toxic to astrocytes at similar concentrations ≥500 μM, inducing cells 
death by apoptosis. Additionally, several other works have shown that METH is toxic to 
neuronal stem cell (Bento et al., 2011; Baptista et al., 2012), and also to cortical and 
striatal cells (Deng et al., 2001, 2002). Nevertheless, low concentrations of METH were 
proved to be non-toxic to endothelial cells (Martins et al., 2013) and microglial cells 
(Coelho-Santos, 2012). Accordingly, based on our results and since our goal was to 
explore the use of METH as a co-adjuvant of chemotherapeutic drugs, in the present 
study we used 1 μM METH, a concentration that did not induced U-118 cell death. This 
METH concentration is also known to be capable of increase endothelial cell 
permeability, without affecting cell death as above mentioned (Martins et al., 2011).  
 Besides METH, the effect of DOX in cell viability was also evaluated and it was 
shown that DOX causes a concentration-dependent cytotoxicity in glioblastoma cells, 
which is in agreement with previous studies (Gopinath et al., 2009; Patil et al., 2012; 
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Nabissi et al., 2013). Moreover, METH did not interfere with the cytotoxic effects 
induced by DOX in glioblastoma cells. The mechanisms by which DOX exerts its 
cytotoxic effects are related to its ability to disturb DNA function and induce DNA 
damage. DOX intercalates into DNA double helices, inhibits topoisomerase II and cross-
link DNA strands (Gewirtz, 1999). Some studies showed that DOX has the ability to 
downregulate Bcl-2 mRNA levels (Leung and Wang, 1999). Bcl-2 is an anti-apoptotic 
protein, whereas Bax is pro-apoptotic, and the balance between both proteins is critical to 
determine the death or survival of the cell. Pro-apoptotic protein Bax is activated and is 
translocated to the mitochondrial membranes, where it causes the loss of mitochondrial 
membrane potential and subsequent cytochrome c release, caspases activation and 
consequently apoptosis (Narita et al., 1998). Here, we only showed a decrease of cell 
viability induced by DOX and to clarify the signaling mechanism(s) involved in such 
effect, further studies are required.  
 Besides DOX, MTX also induced a concentration-dependent cytotoxicity in 
glioblastoma cells. MTX inhibits both deoxythymidine monophosphate (dTMP) synthesis 
and de novo purine synthesis, a result of dihydrofolate reductase (DHFR) inhibition that 
leads to DNA synthesis inhibition and subsequent cell death (Schweitzer et al., 1990). 
Similarly to DOX, METH at low concentration did not interfere in the cell death induce 
by MTX.  
 Regarding TMZ, the current first-line chemotherapeutic agent used in the 
treatment of glioblastoma, it was observed a significant decrease in cell viability only for 
higher concentrations above 500 μM, indicating that U-118 cells are more resistant to 
TMZ. TMZ is an alkylating agent mainly known to act in the formation of O
6
-
methylguanine in DNA, which mispairs with thymine during DNA replication, leading to 
activation of apoptotic pathways. Besides this mechanism of action, it was reported that 
malignant glioma cells can respond to TMZ by arresting cell cycle at G2/M phase and 
escape to apoptosis (Hirose et al., 2001). Additionally, Kanzawa and collaborators (2004) 
reported that TMZ can induce autophagy in glioma cells. The reduced efficacy of TMZ in 
gliomas was initially attributed to the activity of methylated-DNA-protein-cysteine 
methyltransferase (MGMT) which removes the DNA adducts, but recently other 
mechanisms of action and pathways by which glioma cells escape from death are being 
investigated. Carmo and others (2011) suggested that glioma cells escape from TMZ-
induced cell death due to the maintenance of the phosphorylation status of PI3K/Akt and 
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ERK1/2 MAPK kinase. In this present study, no significant effects in cell viability were 
observed between TMZ alone or TMZ plus METH, suggesting that 1 µM METH does not 
interfere in the TMZ cell death mechanisms.  
 
4.2. Effects of methamphetamine and chemotherapeutic drugs on 
glioblastoma cell migration 
 
 Glioblastoma are characterized by their invasive and migratory properties that 
prevent the complete tumor resection and cause neurological morbidity and mortality 
(Giese et al., 2003). Since the aim of this work was to explore the possibility of using 
METH to allow the entrance of chemotherapeutic drugs, it is highly important to evaluate 
if 1 μM METH, alone or together with DOX or MTX, affects glioblastoma migration. 
Firstly, we concluded that METH by itself does not interfere in cells migration. 
 Contrary to METH, it was observed that DOX has the ability to decrease 
glioblastoma cells migration, and to maintain this trend over time. The ability to decrease 
the glioblastoma migration is in agreement with previous studies involving DOX and 
human glioblastoma cells (Gopinath et al., 2009) but also in studies conducted in other 
type of cancers, such as ovarian cancer cells (Brum et al., 2013). This effect, can be 
justified at least in part by the impairment on cell viability since we used the IC50 value. 
Furhermore, Brum and collaborators showed that DOX-induced cell death and inhibition 
of cell migration in ovarian cancer cells are associated with cytoskeletal protein 
reorganization, ataxia telangiectasia mutated (ATM)/p53 activation, and chromatin 
remodeling (Bum et al., 2013). The co-administration of METH did not altered DOX-
induced migratory ability.  
 Regarding MTX, it has also the capacity to decrease glioblastoma migration, and 
once again METH did not alter this effect. The mechanism responsible for the decreased 
of glioblastoma migration induced by MTX is still unknown. However, based on the 
general MTX mechanism of action, it can be hypothesized that the inhibition of 
nucleotide synthesis, which leads to DNA synthesis inhibition (Schweitzer et al., 1990),  
will strongly affect the protein expression in all cells and so affecting migration. 
Specifically, since cell migration is a process that involves a continue expression of 
cytoskeletal proteins, such as actin and tubulin, monomers of microfilaments and 
microtubules responsible for the cellular and intercellular movement (Copper and 
CHAPTER 4 - Discussion 
74 
Hausmann, 2006), the inhibition of DNA synthesis induced by MTX will compromise the 
entire mechanism involved in cell migration. Other studies also showed that MTX 
modifies neutrophils migration which may interfere with cytoskeleton elements and 
metabolic processes (Kraan et al., 2000). However, further studies must be done, in order 
to understand the real mechanism involved in MTX and glioblastoma cells migration. 
 
4.3. Effects of methamphetamine and chemotherapeutic drugs on 
glioblastoma cell chemotaxis 
  
 Chemotaxis is the phenomenon whereby cells direct their movements according to 
certain chemicals in the environment (reviewed by Wang et al., 2011). Chemokines are a 
family of molecules that regulate the chemotaxis of leucocytes in tissues (Gerard et al., 
2001) and more recently recognized as intervenients in the regulation of other cellular 
processes such as survival, tumor growth and angiogenesis (Vandercappellen et al., 
2008). The CXCL12 chemokine and its receptor CXCR4 have been associated with the 
tumorigenesis in brain cancer (Fulton, 2009). When CXCL12 binds to its receptor, 
CXCR4 dimerization happens and the activated complex CXCR4/CXCL12 participates in 
survival, cell proliferation and motility regulation (Barbero et al., 2003). To clarify if 
METH affects the chemotactic ability of glioblastoma cells, a chemotaxis assay was 
performed using the chemokine CXCL12 as chemotaxin. In this present work it was 
observed that glioblastoma cells have a small basal chemotactic ability that significantly 
increases in the presence of CXCL12, which was been demonstrated already in other 
study with U-118 glioblastoma cells (Carmo et al., 2010). Here, we observed a significant 
decreased in glioblastoma cells chemotactic ability in the presence of METH. No specific 
information is available regarding the effect of METH in cells chemotaxis. However, it 
was shown that cocaine inhibits the migratory response of neural precursor cells towards 
CXCL12 stimulus, and this finding was associated with the cocaine ability to induce 
down-regulation of CXCR4 receptor (Hu et al., 2006). Although, additional work is 
required for a comprehensive understanding of how METH alters chemotaxis in 
glioblastoma cells. 
 Regarding DOX it was observed that it had the ability to decrease glioblastoma 
cells chemotactic migration. This effect was maintained when cells were incubated with 
DOX plus METH, with no significant differences between both treatments. Based on a 
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previous study by Carmo and collaborators (2010), the effect of DOX on glioblastoma 
chemotactic migration could be related with its impact on cell survival, motility or 
proliferation pathways induced by CXCR4/CXCL12 complex, the PI3K/Akt pathway 
(Carmo et al., 2010). Moreover, it was demonstrated that topoisomerase II inhibitors lead 
to an increase in ceramide in glioma cells (Sawada et al., 2000), which in turn can induce 
the association between Akt and Protein Phosphatase 1 (PP1) that dephosphorylates Akt 
(Yao et al., 2012) leading to its inactivation. Taking this into consideration, the ceramide 
mediated Akt inactivation will contribute to the anti-chemotactic effect exerted by DOX. 
To clarify whether ceramide and the PI3K/Akt pathway are responsible for this DOX 
anti-chemotactic effect in glioblastoma cells, more studies must be performed.  
 The effect of MTX on glioblastoma chemotactic ability was also explored, and the 
results obtained demonstrated that this antimetabolite has the capacity to decrease the 
chemotactic migration of glioblastoma cells. This capacity was maintained when cells 
were incubated with MTX and METH, once again showing that METH does not 
potentiate MTX-induced impairment of chemotactic migration. Little is known about the 
role of MTX in chemotaxis. However, a recent study performed by Georgiou and 
collaborators (2012) showed a deregulation of CXCL12/CXCR4 axis in bone marrow 
cells treated with MTX, which may be associated with the reduced CXCR4 gene and 
protein expression following MTX chemotherapy. Alterations in gene expression induced 
by MTX could be due to the inhibition of DHFR that results in a depletion of the 
intracellular reduced folate pools required for the biosynthesis of purines and thymidine 
that leads to DNA synthesis inhibition (Schweitzer et al., 1990). This issue would be of 
particular interest to clarify how MTX affects glioblastoma cells chemotaxis.  
 
4.4. Effects of methamphetamine and chemotherapeutic drugs on 
glioblastoma cell cycle  
 
 Previous studies conducted in our lab demonstrated that METH can interfere with 
the cell cycle in hippocampal stem cells (unpublished data). It is also known that 
chemotherapeutic drugs that target DNA, such as DOX and MTX, alter the normal cell 
cycle. So, in the present study our goal was to evaluate the effect of METH alone or in 
combination with DOX or MTX on U-118 cell cycle. 
 Although in previous studies METH had demonstrated an ability to interfere with 
the hippocampal stem cells cycle by inducing a delay in the G1-to-S phase transition and 
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a down-regulation of cyclin E (unpublished data), in the present work METH did not 
significantly altered the cell cycle of glioblastoma cells. Also, no alterations were 
observed in the protein levels of cyclin A and cyclin D1. These results suggest that U-118 
cells are more resistant to METH-induced cell cycle alterations than the hippocampal 
stem cells or neuroblastoma cells (Bachmann et al., 2009). Actually, studies using 
microarrays analysis revealed a down-regulation of cyclin D1 and cyclin A1 genes in 
neuroblastoma cells induced by METH (Bachmann et al., 2009). Regarding this issue, it 
would be interesting to further clarify if there is any alteration in cyclin D1 or cyclin A 
gene expression in glioblastoma cells treated with METH.   
 Concerning the effects of DOX in cell cycle, it was observed a significant increase 
in percentage of cells in the G2/M phase demonstrating a cell cycle arrest at this point. 
Checkpoint protein levels were also analyzed and it was possible to conclude that the 
G2/M phase arrest was accompanied by a decreased in cyclin A protein levels, the protein 
responsible for the G2/M checkpoint. Our results are in agreement with other published 
works involving osteosarcoma cells (Martins-Neves et al., 2012) and breast carcinoma 
cells (Kuznetsov et al., 2011). Additionally, studies performed in cervical cancer and 
melanoma cells showed that cyclin A is activated during normal G2/M progression and 
that this activation is blocked in G2 arrested cells induced by etoposide, a topoisomerase 
inhibitor, which suggests that the G2 phase cyclin A is a target of the G2 phase DNA 
damage response. To reinforce the role of cyclin A in G2/M phase arrest, it was seen that 
the blockade activation of the G2 pool of cyclin A during G2 arrest maintained the cycle 
arrest (Goldstone et al., 2001).  
 This study is in accordance with our showing that DOX is also able to induce a 
G2/M checkpoint arrest by compromising the expression of cyclin A, which limits the 
normal cell cycle progression. Cyclin D1 protein levels were also analyzed, but no 
differences were observed, which is in agreement with cell cycle analyses that did not 
show significant alterations in the percentage of cells in G0/G1 phase. Moreover, METH 
did not significantly interfere with the effect of DOX alone in cell cycle and checkpoint 
regulator proteins. 
 Here, we also explored the effect of MTX in cell cycle. Previous studies have 
shown that MTX exerts its toxicity in melanoma and osteosarcoma cells due to a S phase 
arrest in cell cycle (Sáez-Ayala et al., 2012, Martins-Neves et al., 2012).  In line with 
these studies, MTX also induced a S phase arrest in glioblastoma cells. This arrest was 
accompanied by a significant decreased in the percentage of cells in the G0/G1 phase. 
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Usually, alterations in G0/G1 phase lead to alterations in G0 checkpoint protein 
expression, cyclin D1. Based on this, cyclin D1 and cyclin A protein levels were also 
analyzed but no alterations were observed. These results suggest that the decrease in the 
percentage of cells in G0/G1 and the S phase arrest were not dependent of cyclin D1 nor 
cyclin A protein expression. Thus, one possible explanation for the S phase arrest seen in 
glioblastoma cells could be the depletion of reduced folates required for the production of 
purine deoxyribonucleotides and thymidylate necessary for DNA synthesis and repair 
(Schweitzer et al., 1990). Once again, MTX effects in cell cycle and in checkpoint 
regulator proteins were not altered by METH. 
 Since there were no significant alterations among the cell cycle phases between 
24h and 48 h, it could be suggested that the effects of DOX and MTX last for at least 48h. 
Additionally, our results emphasize that the DOX and MTX effects in glioblastoma cell 
viability, migration, chemotaxis and cell cycle, are related to their ability to interfere with 
DNA synthesis and repair.  
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CHAPTER 5 
Conclusions 
 
 With this work it was demonstrated that METH by itself did not interfere with U-
118 glioblastoma cell viability, migration and cell cycle, but impaired cell chemotaxis. 
Moreover, the effects of DOX or MTX on cell viability, migration, chemotaxis and cell 
cycle were not altered by METH.  
 In conclusion, since METH is able to transiently open the BBB and did not 
interfered with the effects of both chemotherapeutic drugs, it is plausible that METH 
could be considered a co-adjuvant of DOX or MTX for the treatment of glioblastoma. 
Nevertheless, since METH can be an addictive drug, further studies are needed to 
consider this a safe approach. 
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